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Abstract
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the most potent of a group of
persistent organic pollutants (POPs). The aryl hydrocarbon receptor (AhR) has a
high affinity for these dioxin-like compounds with activation increasing
transcription of CYP1A1. The aim of this paper was to measure the agonistic and
potential antagonistic effects of four of the most prevalent and potent dioxin-like
agonists: 3-Methylcholanthrene (3-MC), 2,3,7,8-Tetrachlorodibenzofuran
(TCDF), 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) and 3,3’,4,4‘,5-
Pentachlorobiphenyl (PCB 126), comparing them with TCDD. An example of a
suspected partial agonist (DF 203) and an antagonist (CH 233191) were also
assayed. A method of measurement that uses real-time PCR was calibrated to
quantify the induction of CYP1A1. Potency determination for different incubation
times was also investigated using 3-MC and TCDD. An increase in EC50 (~40
fold) between 4 and 24 hours was observed for 3-MC, whereas a lesser difference
(~4-fold) was seen with TCDD. This showed that time is a clear variable when
measuring CYP1A1 induction. Four individual determinations of the potency of
TCDD at inducing P4501A1 gave an average EC50 = 35 pM (± 5.8 pM),
demonstrating the reproducibility and reliability of the method. Successful
measurement of the agonistic properties of the four compounds was characterised:
3-MC EC50= 2.3 nM (Confidence interval = 1.3 - 3.8 nM); TCDF = 5.8 nM (2.8 -
11 nM); PeCDF = 2.2 nM (1.4 - 3.4 nM); PCB 126 = 765 pM (645 - 907 pM).
However, no antagonistic properties were observed demonstrating that within a
TCDD containing mixture, they will have no effect on the prediction of TCDD-
like toxicity. Nevertheless, the method successfully characterized antagonism in
the positive control compounds, DF 203 and CH 223191.
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1. Introduction
1.1 AhR-ligand dependant transcription of CYP1A1
1.1.1 Aryl Hydrocarbon Receptor (AhR)
The Aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor
which was first characterised by Poland and co-workers in 1976 (Poland et al.,
1976). The AhR regulates the expression of a whole host of genes specifically
CYP1A1 and CYP1A2. AhR has a basic-helix-loop-helix (bHLH) near the N-
terminus. Evidence shows the basic part is for DNA binding and the Helix-loop-
helix (HLH) relates to protein-protein dimerization (Dension et al., 2002;
Whitlock, 1999). AhR belongs to the PAS (Per-Arnt-Sim) family of evolutionary
genes which include drosophila genes; Per and Sim and the mammalian Arnt gene
regions (Whitlock, 1999).
Figure 1.1: Domain structure of AhR – Adapted model of AhR structure from Denison et al.
(2002). bHLH: basic helix-loop-helix, NLS: Nuclear localization sequence, PAS: Per-Arnt-Sim,
A: Per A, B: Per B, hsp90: heat shock protein-90KDa, AhR: Aryl Hydrocarbon Receptor, Arnt:
Aryl hydrocarbon Receptor Nuclear Translocator, DRE: Dioxin responsive element.
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The AhR protein partner Arnt (Aryl Hydrocarbon Receptor Nuclear Translocator)
is also included in this family which all have a bHLH (except Per) binding it both
to the DNA and to other proteins. The precise role of each region is unknown, but
together they influence protein-protein binding, DNA recognition and ligand
binding (Whitlock, 1999). Further along the AhR is the C terminal segment that
contains the transactivation domain. The dormant AhR is found in the cytoplasm
and consists of a multi-protein complex of chaperone proteins (Denison et al.,
2003; Whitlock, 1993) which unbind from the AhR once it has entered the
nucleus. These chaperone proteins include two chaperone proteins called hsp90
(heat shock protein-90KDa), an X-Associated protein (XAP2) and a 23KDa co-
chaperone protein; p23 (Bell and Poland, 2000; Denison et al., 2003). According
to Bell and Poland (2000) the hsp90 may stop the unliganded Ah receptor from
binding with the DNA. The AhR can be induced by both halogenated aromatic
hydrocarbons (HAH) and polycyclic aromatic hydrocarbons (PAH). Induction is
an adaptive response that facilitates detoxification by increasing the levels of
metabolising enzymes.
1.1.2 Cytochrome P450 and CYP1A1
Cytochrome P450 is a diverse super family of hemoproteins, which in humans,
can be found in the inner membrane of the mitochondria or the endoplasmic
reticulum. The cytochromes metabolise thousands of endogenous and exogenous
compounds and play an important role in hormone synthesis and breakdown. It is
the most important element of oxidative metabolism in humans. Activation of the
AhR will induce the transcription of P450 enzymes including CYP1A1.
Richard Wall
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CYP1 enzymes are usually involved in drug and steroid metabolism. CYP1A1 is a
gene located on chromosome 15 between 15q22 and 15q24 which encodes the
P450 enzyme CYP1A1, involved in xenobiotic and drug metabolism. Normally,
CYP1A1 has a role in xenobiotic metabolism in which it oxygenates lipophillic
compounds to inactive compounds however there is evidence that shows oxidative
DNA damage due to the breakdown products (Park et al., 1996).
1.1.3 Activation of AhR-mediated events
The AhR is activated by specific ligands which must display binding specificity to
activate the receptor. Once binding of the ligand to the AhR has occurred, the
ligand-AhR complex undergoes a conformational change leading to the AhR
exposing the nuclear localising sequence. The ligand-AhR complex translocates to
the nucleus (Hord et al., 1994; Pollenz et al., 1994), where the chaperone complex
unbinds from the ligand-AhR allowing the complex to bind with another protein
called Arnt producing a heterodimer. Binding of the ligand-AhR complex with
Arnt has been shown to increase the binding affinity for DNA (Hankinson et al.,
1995; Probst et al., 1993; Whitlock, 1993).
Richard Wall
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Figure 1.2: The mechanism of ligand activated AhR transcription – 1: Binding of AhR to
ligand. 2: Translocation from cytoplasm to nucleus. 3: Unbinding of chaperone proteins from
AhR. 4: Binding of AhR and Arnt to form heterodimer. 5: Binding of AhR:Arnt complex to DRE.
6: Transcription of CYP1A1 RNA. AhR: Aryl hydrocarbon receptor, Arnt: Aryl hydrocarbon
Receptor Nuclear Translocator, DRE: Dioxin responsive element. Figure was adapted from
Denison et al. (2003).
An enhancer is located upstream of the CYP1A1 coding region and contains
multiple copies of binding sites for the AhR-Arnt heterodimer (Denison et al.,
1988a; Denison et al., 1988b). These specific locations are known as xenobiotic-
or dioxin-responsive elements (XRE or DRE) and have the sequence of 5’-
TNGCGTG-3’ (Denison et al., 1988a; Whitlock, 1999). The more proximal
control element has the functional properties of a transcriptional promoter, located
immediately upstream of the CYP1A1 gene (Jones et al., 1990). The promoter
contains several other binding sites for other transcriptional factors but not for
AhR or Arnt. The promoter contains a guanine-rich region, a TATA box and
CCAAT box transcriptional factors (Whitlock, 1999). The promoter requires an
Ligand
AhR complex
Chaperone
Proteins
Arnt
CYP1A1 RNA
AhR:Arnt:DRE
1.
2.
3.
4.
5.
6.
Cytoplasm
Nucleus
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operational enhancer and all protein-DNA interactions are AhR and Arnt
dependant. Therefore it has been suggested that the enhancer controls the
promoter, with the prospect that the promoter attaches in some way to the
AhR/Arnt complex with the enhancer via the TATA box, folding the DNA
(Whitlock, 1999).
1.2 Ligands of AhR and Agonism
1.2.1 Definition of Agonism
Interactions of ligands with receptors are assumed to follow the law of mass
action, with the way they interact with the receptor measured by two properties,
affinity and efficacy. Affinity is the property of attraction between a ligand and
the receptor, whereas efficacy is the property that allows the ligand, once bound,
to produce a response (Kenakin, 1997). This allows ligands to be split into several
categories of full agonists, partial agonists, antagonists and inverse agonists.
Another property allowing ligands to be categorised and compared is intrinsic
efficacy. Intrinsic efficacy is the measure of the stimulus per unit of drug-receptor
complex (Urban et al., 2007). A full agonist would have a high intrinsic efficacy
whereas a competitive antagonist would have none, however the antagonist would
still bind to the receptor blocking interaction with an agonist. A full agonist will
produce a maximal response irrelevant of its affinity for the receptor whereas a
pure antagonist won’t produce any response. A partial agonist has a lower
intrinsic efficacy than a full agonist and does not produce a maximal response
irrelevant of the dose. It would be assumed that a full agonist would work as
efficiently as the endogenous ligand for that receptor, however in the instance of
the AhR, a receptor responsible for xenobiotic metabolism, the exact endogenous
Richard Wall
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ligand is unknown as the receptor binds to a large variety of ligands both synthetic
and naturally occurring. Potency is the expression of the activity of the ligand in
terms of concentration or the amount needed to provide an observable response
(Jenkinson et al., 1995). The effective dose at which provides 50% of the maximal
response (EC50) can be used to estimate the potency of an agonist. The lower the
concentration needed for an effect, the higher the potency. TCDD is one of the
most potent inducers of the AhR. A competitive antagonist will compete with the
agonist for the receptor but can be over come by increasing the concentrations of
the agonist. This means the dose-response curve will shift to the right but the
agonist will still have the same maximal response. Contrary to this is non-
competitive antagonism where the antagonist binds at a different site from the
agonist, or binding covalently to the same site and can’t be overcome by
increasing the concentration of agonist.
The definition of a partial agonist; is an agonist which binds with high affinity to a
receptor, but activates only a small proportion of receptors hence a low efficacy.
In some instances the agonist may appear to have only agonist properties but
when in the presence of another compound, may also elicit antagonist effects by
reducing the potency of the other compound. Schild regression analysis is a useful
way of estimating the agonist or antagonistic response caused by the receptor.
Using a dose response curve of the agonist in the presence and absence of various
concentrations of antagonist, it is possible to calculate the potency of a partial
agonist or antagonist (Calderone, 1998).
Richard Wall
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1.2.2 AhR agonists
1.2.2.1 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is the most potent of a family of
halogenated aromatic hydrocarbons (HAHs). TCDD induces a diverse spectrum
of phase I and phase II drug metabolising enzymes including CYP1A1, CYP1A2
and CYP1B1, and their dependant activities, glutathione s-transferase,
glucuronosyl transferase and NAD(P)H quinine oxidoreductase (Safe, 1986;
Whitlock, 1993). Proteins modulated by TCDD include growth and diffentiation,
cytokines, xenobiotic metabolising enzymes and enzymes involved in the
metabolism of fatty acids. TCDD is both highly stable and lipophillic, and is also
one of the most potent known CYP1A1 inducers (Whitlock, 1993). TCDD is
relatively resistant to metabolism and has a half life of 17-31 days in rats and 10
years in Humans (Van den Berg et al., 1994; Whitlock, 1993).
O
OCl
Cl
Cl
Cl
2,3,7,8-Tetrachlorodibenzo-p-dioxin
Figure 1.3: Chemical formula for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
TCDD is absorbed primarily through the consumption of dairy and fat, where it
accumulates. In animals, TCDD has differing effects with a wide range of
biological effects including changes to metabolic pathways, immunological
changes, teratogenic effects and neoplasia (Poland et al., 1982; Safe, 1986;
Walker et al., 2005; Whitlock, 1993). TCDD originated as a by-product of plastic
and general industrial manufacture, but its production, even unintentional, was
Richard Wall
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banned in the 1970-1980s. The TCDD levels in the environment have decreased
over the last three decades but TCDD is still a much studied compound due to its
much higher toxicity compared to other, more abundant environmental pollutants.
One of the most notable endpoints of TCDD poisoning is Chloracne, an acne-like
eruption of black heads (Tindall et al., 1985). There is also evidence that TCDD
causes an increased likelihood of cancer in humans (Manz et al., 1991) but most
research agrees that even the highest environmental background level of TCDD
will not increase the initiation of cancer (Aylward et al., 1996; Bertazzi et al.,
1989; Brown et al., 1998). Furthermore, evidence suggests that TCDD is more of
a promoter than an initiator, with humans being less sensitive to TCDD than
animal models (Aylward et al., 1996; Ema et al., 1994; Harper et al., 2002).
During the Vietnam War, Agent Orange was a herbicide used by the Americans to
remove the foliage covering the Vietnam army. The herbicide, which rapidly
increases plant leaf growth before defoliating them, was a mixture of two
chemicals: 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-
trichlorophenoxyacetic acid (2,4,5-T). However, it was later found that the
herbicide contained TCDD as a by-product in the production of 2,4,5-T. Authors
have found large concentrations of TCDD in milk lipid and blood samples of the
people involved in the dispersal of the herbicide but have found that current levels
are decreasing to that found in industrialised areas (Kahn et al., 1988; Schecter et
al., 1995).
1.2.2.2 3-Methylcholanthrene (3-MC)
3-Methylcholanthrene (3-MC) is a polycyclic aromatic hydrocarbon produced
when burning organic compounds at very high temperatures. It is a known potent
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carcinogen, implicated in prostate cancer, which is used in study models as an
inducer of cancer (Malins et al., 2004; Sekimoto et al., 2004; Wood et al., 1978;
Xu et al., 2005).
3-Methylcholanthrene
Figure 1.4: Chemical formula for 3-Methylcholanthrene (3-MC)
Poland and Glover (1974) demonstrated that 3-MC activated the AhR and induced
CYP1A1. The authors also found that induction by 3-MC decreased with time,
explaining this as metabolism. This has since been confirmed by other authors,
although the comparison of potency and affinity with TCDD previously quoted by
Poland and Glover (1974) has been considerably refined (Riddick et al., 1994;
Sekimoto et al., 2004; Xu et al., 2005). Research has shown the 3-MC has a
slightly lower binding affinity (Okey et al., 1982) and a lower potency (Riddick et
al., 1994) in comparison to TCDD.
1.2.2.3 2,3,7,8-Tetrachlorodibenzofuran (TCDF) and 2,3,4,7,8-
Pentachlorodibenzofuran (PeCDF)
2,3,7,8-Tetrachlorodibenzofuran (TCDF) and 2,3,4,7,8-Pentachlorodibenzofuran
(PeCDF) are both polychlorinated dibenzofurans. TCDF is a halogenated aromatic
hydrocarbon which has no known industrial use but is still widespread in the
environment (Birnbaum et al., 1980). Both TCDF and TCDD have a similar
structure with TCDF having a slightly lower affinity for the AhR (Safe et al.,
1990).
CH3
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O
Cl
Cl
Cl
Cl
O
Cl
Cl
Cl
Cl
Cl
2,3,7,8-Tetrachlorodibenzofuran 2,3,4,7,8-Pentachlorodibenzofuran
Figure 1.5: Chemical formula for 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) and 2,3,7,8-
Tetrachlorodibenzofuran (TCDF).
Polychlorinated dibenzofurans (PBDFs) are often found as a by-product of PCB
production although the only large scale incident of exposure was in Japan
(Masuda et al., 1985). Symptoms are similar to that of TCDD and include
chloracne, gastrointestinal problems and fatigue. PeCDF is an important dioxin-
like compound because it contributes a considerable amount to the TEQ
estimation (Budinsky et al., 2006). TCDF has a half-life of only 2 days in rats
suggesting the compound is rapidly metabolised (Birnbaum et al., 1980; Clemons
et al., 1997).
1.2.2.4 3,3’,4,4‘,5-Pentachlorobiphenyl (PCB 126)
Polychlorinated biphenyls (PCBs) have the same mechanism of action as dioxin-
like compounds with 3,3’,4,4‘,5-Pentachlorobiphenyl (PCB 126) being the most
potent of them. PCBs had a wide spread use until they were banned in the 1970s
due to their high toxicity and ability to bioaccumulate. PCBs were used as
coolants for transformers and stabilizing additives in electrical insulation, flame
retardants, sealants and adhesives.
Richard Wall
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Cl
Cl
Cl
Cl
Cl
3,3’,4,4‘,5-Pentachlorobiphenyl
Figure 1.6: Chemical formula for 3,3’,4,4‘,5-Pentachlorobiphenyl (PCB 126)
Induction of PCB 126 is well researched estimating it to be approximately 10-fold
less potent than TCDD (Peters et al., 2004; Sanderson et al., 1996; Silkworth et
al., 2005). Due to this large amount of research on PCB 126, the WHO have
authorised its use as a reference compound, as an alternative to TCDD (Van den
Berg et al., 2006).
1.2.3 AhR Partial Agonists and Antagonists
1.2.3.1 DF 203
Also tested in this study was a putative partial agonist: 2-(4-Amino-3-
Methylphenyl)Benzothiazole (DF 203). DF 203 is a synthetic anti-tumour agent
(Chua et al., 2000; Elferink et al., 2003; Loaiza-perez et al., 2002), which has
known agonist properties (Bazzi, 2008; Chua et al., 2000; Loaiza-perez et al.,
2002). However, studies by Bazzi (2008) demonstrate that the compound has a
high binding affinity (Ki = 9.9 nM 95% CI = 5.3 - 18.17 nM) but through
CYP1A1 induction assays, found that DF 203 is a weak agonist. This difference
between the high binding affinity and low efficacy may indicate that DF 203 has
partial agonistic/antagonistic properties.
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NH2
2-(4-Amino-3-Methylphenyl)Benzothiazole
Figure 1.7: Chemical formula for 2-(4-Amino-3-Methylphenyl)Benzothiazole (DF 203)
When sensitive cells are treated with DF 203, it is metabolised to 2-(4-
aminophenyl-3-methylphenyl)-6 -hydroxybenzothiazole (6-OH 203 or IH 130). 6-
OH 203 is a potential antagonist that inhibits CYP1A1 (Bazzi, 2008).
1.2.3.2 CH 223191
As well as compounds inducing the AhR and increasing the transcription of
CYP1A1, there are also compounds which inhibit induction called antagonists.
One example of an AhR antagonist is 2-methyl-2H-pyrazole-3-carboxylic acid (2-
methyl-4-o-tolylazo-phenyl)-amide (CH 223191) (Bazzi, 2008; Kim et al., 2006).
N
NN N N
O
H
CH3
CH3
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide
Figure 1.8: Chemical formula for 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-
tolylazo-phenyl)-amide (CH 223191)
Bazzi (2008) demonstrated that even at concentrations of 10 µM, CH 223191
showed no agonist effects, concluding that it was a pure antagonist. Kim et al.,
(2006) showed that CH 223191 prevented toxic responses caused by TCDD in
both in vivo and in vitro models, concluding that it could be used as a preventative
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agent against TCDD-related toxicity (Kim et al., 2006). TCDD, in the presence of
a suitably large concentration of this compound, should have no effects on
induction of CYP1A1, however at lower concentrations of CH 223191, the
antagonist will have partial effects on the induction threshold but at some point
the concentration of TCDD will overpower the antagonist.
1.3 Human Health
1.3.1 Persistent Organic Pollutants
Dioxins, Furans and Polychlorinated biphenyls (PCBs) are all persistent organic
pollutants (POPs). Dioxins and furans have been unintentionally produced in the
production industry or by incineration. It’s generally accepted that these POPs all
undergo a similar pathway of toxicity. The aryl hydrocarbon receptor (AhR) has a
high affinity for certain dioxin-like compounds. Activation of the AhR increases
the transcription of CYP1A1 which is involved in xenobiotic metabolism. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD) is an agonist of the AhR and is the most
characterised of the AhR ligands. Due to the complex mixtures of POPs in the
environment, toxic equivalency factors (TEF) for the majority of dioxin-like
compounds have been established to allow risk assessment of the toxic effects of
dioxin congeners. These are calculated in relation to TCDD and can be used to
determine the total toxic TCDD-equivalent dose (TEQ) (Van den Berg et al.,
2006).
1.3.2 Toxic Equivalency Factors
In 2005, the World Health Organisation (WHO) re-evaluated a method of
estimating the toxic potency of environmental mixtures (Van den Berg et al.,
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2006). The method involves estimating the relative effect potency (REP) for each
compound which had been derived from various research studies on each
chemical. At the meeting, the committee used this data to calculate the toxic
equivalency factor (TEF). In the environment these AhR agonists are in complex
mixtures so it is necessary to estimate the toxicity of the whole mixture. An
additivity method is used which combines each individual TEF in the mixture and
multiplies it with the concentration. This new value is known as the total toxic
equivalency (TEQ) and is used to estimate the total TCDD-like activity of the
mixture (Van den Berg et al., 2006).
Congener TEF Value
2,3,7,8-TCDD 1.0
1,2,3,7,8-PeCDD 1.0
1,2,3,6,7,8-HxCDD 0.1
OCDD 0.0003
2,3,7,8-TCDF 0.1
2,3,4,7,8-PeCDF 0.3
1,2,3,7,8-PeCDF 0.03
1,2,3,6,7,8-HxCDF 0.1
PCB 77 0.0001
PCB 81 0.0003
PCB 126 0.1
PCB 169 0.03
Table 1.1: TEF Values - Shows a selection of examples for TEF values for dioxin-like
compounds (Van den Berg et al., 2006).
The TEF for each compound is calculated in comparison to a reference
compound, TCDD. In order for a compound to be included in the TEF system it
must have a similar structural relationship to Polychlorinated dibenzo-p-dioxins
(PCDDs) and undergo the same mechanism of toxicity via the AhR receptor. The
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compound also needs to be persistent and show signs of biomagnification. (Van
den Berg et al., 2006). A database of information on REP distribution and point
estimates was established by Haws et al. (2006). With regards to error calculation,
the authors describe the method as quantitative allowing uncertainty analysis to
measure the strength of the REP calculated (Haws et al., 2006). The REP is
calculated using dose-response curves for the agonist and TCDD. The EC50 of the
TCDD curve is divided by the EC50 of the agonist however this system requires
that the same maximum response is reached by both compounds. Further work
has concentrated on how the REPs are estimated and weighted to produce the
TEF. This includes problems with the data used to estimate the TEF which can be
derived from different dosage methods making a large difference in the potency
estimation of the TEF (Devito et al., 1995). Therefore the WHO meeting
concluded that a standardized method of estimating the REP was required before
it can be used to further estimate the TEF. However the main issue, which will be
discussed further, relates to the method of predicting the TEQ of a mixture by
applying the additivity approach and factors which may affect it.
1.3.3 Limitations of TEQ predictive method
Although AhR agonists have varying potencies, it is thought that they all undergo
a similar pathway of toxicity by binding to the AhR, and causing ligand-
dependent induction of a gene battery (Whitlock, 1993; Wu and Whitlock, 1993).
It is therefore believed that the relative potency of each compound in a mixture, in
relation to concentration, can be added together to predict the potency of the full
mixture. The additivity method used to calculate the TEQ, combines each
individual TEF in the mixture and multiples it with the concentration. This system
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assumes that all the compounds are agonists and will have no antagonist activity
in the presence of other AhR agonists. However, if an AhR agonist also has
antagonistic properties, this would affect the overall toxic potency of the mixture
by potentially reducing it. An evaluation of the TEF and TEQ process by the
WHO stated that more research needs to be done in this area (Van den Berg et al.,
2006). Numerous authors have undertaken experimental analysis of the additivity
approach and demonstrated the reliability of the method for risk assessment
(Ahlborg et al., 1994; Fattore et al., 2000; Hamm et al., 2003; Safe, 1990, 1994;
Walker et al., 1996). A more recent study into mixture characteristics was done by
Walker et al., (2005) assessing the TEF additivity model by assaying TCDD, PCB
126 and PeCDF, individually and in a mixture. The authors concluded that the
TEQ system did not accurately predict potency but instead supported the use of a
potency adjusted dose-additive approach discussed in a previous paper
(Toyoshiba et al., 2004). Using this method, the authors support the future use of
the TEF system in cancer risk assessment (Walker et al., 2005). Toyoshiba and
co-workers (2004) disagreed with the additivity approach used by the WHO TEQ
comparing it unfavourably against same-shape fit and simple additivity models
(Toyoshiba et al., 2004). They concluded that, due to differences in dose-response
shape of compounds and the lack of dose additivity, the relative potency factors
used to calculate the TEFs are not consistent with the WHO TEFs.
Further concerns include the use of the additivity approach for the use of dietary
intake predictions. Due to the presence of naturally occurring AhR agonists and
antagonists in the body, accurate prediction of TEQ becomes very complicated
(Safe, 1998). An example of a naturally occurring antagonist is resveratrol (3,5,4’-
trihydroxystilbene) found in red wine. According to research by Casper et al.,
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(1999), resveratrol competes with TCDD and other AhR ligands, and inhibits the
induction of CYP1A1. The antagonist binds to the AhR receptor, displacing
TCDD, translocates to the nucleus and binds to the relevant enhancer site on the
DNA but doesn’t induce transcription of the CYP1A1 gene (Casper et al., 1999).
Zhang et al. (2003) measured the agonist/antagonist effects of several flavonoids
and found that three of the compounds, kaempferol, quercetin and Luteolin, had
antagonistic effects in the presence of TCDD whereas a selection of the other
ligands tested had slight agonist properties including chrysin. Other examples of
natural AhR ligands include bilirubin (Phelan et al., 1998), indole-3-carbinol
(Bjeldanes et al., 1991; Gillner et al., 1985), resveratrol (Casper et al., 1999;
Ciolino et al., 1998) and flavones (Henry et al., 1999).
Some mixture studies conducted have shown inconclusive results, with the
authors commenting that mixtures could be additive, antagonistic or synergist, and
concluded that a better understanding of mechanisms of action or the
toxicokinetic behaviour was required for future predictions (Chu et al., 2001;
Safe, 1998). With respect to inter-species differences, Pohjanuita and co-workers
(Pohjanuita et al., 1995) showed the varying effects of TCDD-like compounds
between different strains of rat, demonstrating a potential problem when
calculating the TEF by using REPs from different strains. Furthermore, complex
mixtures can contain compounds that act through different metabolic pathways
and therefore the additivity approach may not always be appropriate (Safe, 1998).
Another potential problem is super-induction, which occurs in a particular TCDD
containing mixture, where CYP1A1 is transcribed at a higher rate than by TCDD
alone although it decreases protein translation (Lussaka et al., 1992, Ma et al.,
2000). If translation has been inhibited leading to a build up of CYP1A1 RNA, the
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toxicity of a mixture could be affected, implying the predicted risk assessment
TEQ maybe too high.
However, one of the leading concerns associated with the WHO TEQ additive
approach is the application of the method to a mixture containing partial agonists
and antagonists, which may reduce the TCDD-like effects of the mixture. Some of
the most documented examples of partial agonists, from a TEQ point of view, are
a selection of PCBs which have been found to have both agonistic and
antagonistic properties (Clemons et al., 1998; Chu et al., 2001; Schmitz et al.,
1995; Suh et al., 2003). Clemons et al. (1998) combined various concentrations of
TCDD with different PCBs and showed that some of the PCBs had antagonistic
effects which would produce a lower toxic effect than that predicted by the TEQ
additivity approach. This conclusion was further complicated by the differing
effects of antagonistic PCBs in complex mixtures of HAHs (Clemons et al.,
1998).
This paper will assay a selection of the most potent and prevalent dioxin-like AhR
ligands to assess any potential antagonist properties. These include Dioxins
(TCDD), Furans (TCDF and PeCDF) and PCBs (PCB 126). Also tested in this
study will be a polycyclic aromatic hydrocarbon (3-MC). If antagonism/partial
agonism is exhibited by any of the compounds tested in this assay, Schild
regression analysis can be used to measure the potency of the antagonist. This
experiment will also use an example of both a putative partial agonist (DF 203)
and an antagonist (CH 223191).
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1.4 Measurement of AhR activation
1.4.1 CYP1A1 Induction
The reasons that in vitro models were used over in vivo include: the ease of
dosing, allowing the maximal effect to be reached at very early time points. Cells
are exposed to the full concentration directly without, for example, gradual uptake
from digestion or reduction by metabolism. This also means that the cells are
exposed to compounds without initial metabolism by liver or bioaccumulation in
adipose tissue, allowing lower doses of compounds to be used and permitting a
more reliable estimation of the EC50. Liver cells have a large amount of AhR in
comparison to other cell types. Also taken into account, is the reduced cost and
simplicity of in vitro models and finally the low basal CYP1A1 levels which can
be easily induced. Previous confirmation of the presence of AhR in H4-IIECE
cells has been achieved (Bazzi, 2008). It is generally accepted that the most
sensitive way to measure the activation of the AhR is through the measurement of
CYP1A1 RNA as it is one of the most potent effects of AhR activation. The
reasons that CYP1A1 induction is measured are three-fold; firstly induction is
robust, with a high signal to noise ratio; secondly, induction occurs in both in vivo
and in vitro models, allowing the use of cultured cells (Whitlock, 1999). Finally,
induction allows genetic analysis of the mechanism of action due to the
possibilities of induction-defective mutants; however this is not a required factor
in this particular experiment (Whitlock, 1999).
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1.4.2 Measurement of CYP1A1 RNA by Real-Time PCR
To measure partial agonism of the test compounds in this study, cells will be
treated with various concentrations of TCDD with a set concentration of potential
antagonist. This allows a more accurate calculation of the antagonistic properties
of the test compound by measuring the shift of the dose response curve to the
right. This gives more information on the compound in question compared with
adjusting the concentration of antagonist and using a set concentration of TCDD.
A low dose of antagonist is used so accurate calculation of the EC50 can be
conducted while at the same time, 15% induction is large enough to be
significantly different over the baseline level of CYP1A1 RNA. One of the most
accurate ways of measuring mRNA is by using Real-Time PCR (RT-PCR) which
gives a real time view of mRNA. This is done through the measurement of PCR
cycling threshold (Ct) values, defined as the cycle in which the mRNA recorded is
above a particular threshold. The Ct values are calculated for CYP1A1 and two
reference genes, AhR and ȕ-Actin, by the Mx4000 software. The PCR efficiency,
which measures the efficiency of each PCR cycle, can also be calculated using
this software. Further analysis using the Ct values is conducted using Qbase
software. Qbase will normalise the CYP1A1 RNA Ct values against the two
reference genes, AhR and ȕ-Actin, which should be unaffected by treatment. This
calculates the normalised relative amount of CYP1A1 RNA in the sample. The
normalised data is then plotted on to a dose-response graph to allow comparison
between different compounds using the dose that gives 50% of maximal response
(EC50) and its 95% confidence intervals.
Richard Wall
21
Aims
Measure the agonistic and the potential antagonistic effects of 3-MC, TCDF,
PeCDF and PCB 126, comparing them with TCDD. An example of a known
partial agonist (DF 203) and an antagonist (CH 233191) will also be assayed.
1. Calibrate a method of accurately measuring CYP1A1 RNA using real-time
PCR in H4-IIEC3 rat liver cells.
2. Measure the induction of AhR by various agonists and partial agonists
using H4-IIEC3 cells.
3. Locate/measure any potential antagonist effects of the known agonists by
combining them with various concentrations of TCDD in H4-IIEC3 cells.
4. Establish whether time affects the induction of CYP1A1.
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2. Method
2.1 Reagents
2.1.1 Cell Culture Chemicals
x Rat hepatoma H4-IIEC3 cells cat # 85061112
x Minimum essential medium eagle (MEM) 100x cat # M2279
x Non essential amino acid solution 100x cat # M7145
x Fetal bovine serum cat # F7524
x L-Glutamine-penicillin-streptomycin 100x solution cat # G1146
x Dulbecco's phosphate buffered saline cat # D8537
x Trypsin-EDTA solution 10x cat # T4174
The H4-IIECE cells and the medium reagents were purchased from Sigma
(Dorset, UK).
2.1.2 Kits and Reagents
The ‘Absolutely RNA® Miniprep Kit’ (Catalogue #400800), ‘AffinityScipt
QPCR cDNA Synthesis Kit’ (Catalogue #600559) and ‘Brilliant® Multiplex
QPCR Master Mix’ (Catalogue #600553) were purchased from Stratagene
(Amsterdam, The Netherlands).
‘Quanti-iT TM Ribogreen® RNA’ assay kit (Catalogue #R11490), ‘Quanti-iT TM
Picogreen® dsDNA’ assay kit (Catalogue #P7589) and ‘DNA ladder 1kb plus’
(Catalogue #10488-085) were purchased from Invitrogen Molecular Probes
(Paisely, UK).
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2.1.3 Compounds and Solutions
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) (purity 99%, catalogue # ED-901-
B) was purchased from Cerilliant Cambridge Isotope Laboratories (Middlesex,
UK). A 155M top stock of TCDD was made with dimethyl sulfoxide (DMSO)
which was kept at room temperature and protected from light. Further dilution of
TCDD was done in DMSO to 10 µM which was aliquoted into eppendorf tubes
and stored at -20oC. All further dilutions of TCDD were made using ‘24hr old’
medium, giving a final DMSO concentration of <0.02%.
3-Methylcholanthrene (3-MC) (purity 98%, catalogue # 213942) was purchased
from Aldrich. An initial top stock of 20 mM 3-MC was made by diluting in p-
dioxane and stored at -20oC. The compound was also protected from light. Further
dilutions were made using ‘24hr old’ medium, giving a final DMSO concentration
of ~0.01% and a final concentration of <0.001% p-dioxane. Visual inspection
confirmed solubility (no analytic confirmation).
.
2,3,7,8-Tetrachlorodibenzofuran (TCDF) (Purity 98%, catalogue # EF-903-C)
and 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) (Purity 98%, catalogue # EF-
956-C) were both purchased from Cerilliant Cambridge Isotope Laboratories
(Middlesex, UK). A top stock of 100 mM was made for both compounds by
diluting them into DMSO and stored at -20oC. Further dilutions of each
compound were made using ‘24hr old’ medium, giving a final DMSO
concentration of <0.02%
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3,3’,4,4‘,5-Pentachlorobiphenyl (PCB 126) (Purity 98%, catalogue # PCB-126-
C) was purchased from Cambridge Isotope Laboratories (Massachusetts, US). A
top stock of 10 mM was made by dilution in DMSO. This was stored at -20oC
with further dilutions made using ‘24hr old’ medium, which gave a final DMSO
concentration of <0.02%.
2-(4-Amino-3-Methylphenyl)Benzothiazol (DF 203) was produced by Cancer
Research Laboratories at the University of Nottingham (UK) and the Drug
Synthesis and Chemistry Branch (NCI) following published methods (Hutchinson
et al., 2001). The compound was kindly provided by Dr Tracey Bradshaw. A top
stock of 10 mM was stored at -20oC and protected from light. Further dilutions of
DF 203 were made using ‘24hr old’ medium, giving a final DMSO concentration
of <0.02%.
CH 223191 (2-Methyl-2H-Pyrazole-3-Carboxylic Acid (2-Methyl-4-o-Tolylazo-
Phenyl)-Amide) (purity 95.71%) (Catalogue # 182705) was purchased from
Calbiochem (Nottingham, UK). A 10 mM top stock was made by dilution into
DMSO. The solution was stored at -20oC and protected from light. Further
dilutions were done using ‘24hr old’ medium, giving a final DMSO concentration
of <0.02%.
2.1.4 Solutions, Buffers and Medium
Lysis buffer-ȕ-ME: 0.7 ȝl ȕ-ME + 100 ȝl Lysis Buffer (Absolutely RNA®
Miniprep kit).
RNase-Free DNase I: 50 ȝl of DNase Digestion Buffer + 5 ȝl of reconstituted
RNase-Free DNase I (Absolutely RNA® Miniprep kit).
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De-proteinated water (DEPC treated water):
- 1 ml Diethyl Pyrocarbonate
- 9 ml Ethanol
- Distilled water to make up to 1 Litre (autoclaved after mixing to neutralise)
10X TBE buffer:
- 108 g Tris
- 55 g Boric Acid
- 40 ml 0.5M EDTA pH 8
- Distilled water to make mixture up to 1 Litre
10X Loading dye:
- 50% Glycerol
- 0.25% Bromophenol Blue
- 0.25% Xylene Cyanol FF
- 1 nM Ethylenediaminetetreacetic Acid (EDTA)
Complete Medium:
- 500 ml Essential Medium
- 50 ml Fetal Bovine Serum
- 5 ml L-Glutamine-Pencillin-Streptomycin Solution
- 5 ml Non-essential Amino Acids
1X TE buffer: pH 7.5
- 1 ml 20X TE Buffer
- 19 ml Purified Water
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2.2 Measurement of CYP1A1 induction
2.2.1 Cell culture
2.2.1.1 Cell growth curve
H4-IIECE rat liver cells (H4-IIE) were used because of their fast life cycle and
rapid exponential growth. A cell growth curve was constructed by counting cells
with a haemocytometer, showing that total confluence of a 25cm2 flask could be
accomplished within 7 days when starting from a concentration of 10 ×105¢/ml.
H4-IIEC3 cells were cultured in 96 well plates in 180 µl medium which was
changed after 96 hours. At the same time everyday cells were trypsinised with 60
µl trypsin, washed in 60 µl PBS and counted using a haemocytometer. This was
done for 8 days generating a graph of cell growth.
2.2.1.2 Maintenance
When the flasks reached total confluence there was approximately 300 x 106 cells.
All solutions are pre-heated to 37oC before being added to the cells. Passaging
involved removing the old medium from the flask and washing the cells with 3 ml
PBS. The PBS is removed and 1.5 ml trypsin added and incubated at 37oC for 1
minute. 3.5 ml of new medium is added and mixed with the trypsin-cell mixture to
neutralise the trypsin. 9 ml of new medium is then added to a clean flask with 1
ml of the cell mixture. Cells are stored in an incubator at 37oC at 5% CO2. All
experiments were conducted between passage no. 8 and 22.
2.2.1.3 Treatment
Cells were cultured on a 96 well plate using a similar method to that used in
section 2.2.1.2 but with the following exceptions. Initially, 200µl of cell mixture
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is added to each well and allowed to settle for 2/3 days and until total confluence
is reached or 90% confluence in the case of cells treated for 24 hours. Cells were
washed with PBS then treated with particular mixture or compound. Each partial
agonism assay will be split into two separate experiments: 1) location of the
concentration of agonist which gives 15% of the maximal response, 2) treatment
of cells with various concentrations of TCDD in the presence of the concentration
found in the first experiment (with the exception of CH 233191, where the
concentrations were derived from Kim et al., 2006). Table 2.1 gives an example
of concentration calculations for TCDD in the presence of 300 pM 3-MC.
Initially, the concentration of TCDD will be ~10% higher before addition of
medium containing the agonist is added to the solution; this gives more accurate
final concentration for both compounds.
Ref.
Final TCDD
Medium
Volume Total after Volume of
Concentration of TCDD transfer 3 nM 3-MC
A 100 nM 990µl 10µl of 10 µM 900µl 100µl
B 10 nM 900µl 100µl of 100 nM (A) 690µl 77µl
C 3 nM 490µl 210µl of 10 nM (B) 700µl 78µl
D 1 nM 900µl 100µl of 10 nM (B) 690µl 77µl
E 300 pM 490µl 210µl of 1 nM (D) 700µl 78µl
F 100 pM 900µl 100µl of 1 nM (D) 710µl 79µl
G 30 pM 490µl 210µl of 100 pM (F) 700µl 78µl
H 10 pM 720µl 80µl of 100 pM (F) 730µl 81µl
I 1 pM 630µl 70µl of 10 pM (H) 700µl 78µl
J Untreated with 3MC - - 600µl 67µl
K Untreated - - 600µl 0µl
Table 2.1: Dosing concentrations - Dilutions of concentrations used to dose H4-IIECE cells with
various concentrations of TCDD in the presence of 300 pM 3-MC. Table shows final
concentration of TCDD, however a slightly higher concentration is used initially which is reduced
when the medium containing agonist is added (e.g. 900µl 110 nM TCDD + 100µl 3 nM 3-MC =
1000µl 100 nM TCDD and 300 pM 3-MC). ‘Medium’ indicates 24 hour old medium (see section
2.2.1.3.)
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The treatments were made freshly, with visual inspection of solubility (not
analytical) and then added to cells. Agonist only treatments were designed using a
similar method. Both assay types were dosed for 4 hours. For the time dependant
induction assays, cells were treated with various concentrations of the agonist for
either 4 or 24 hours. The concentrations are made up of 24 hour old medium, 0.1-
0.2% DMSO and the particular treatment. 24hr old medium is medium which has
been in the presence of a small quantity of cells for 24 hours and is used because
of the presence of indirubin, an AhR agonist, found in fetal bovine serum (Adachi,
2001), which decreases after 24 hours. Doses contained only <0.02% DMSO
which was found not to be toxic at such low concentrations. Controls included in
the experiment may include; agonist/antagonist only control (AC) and 10 µM
TCDD only control (TC) with all experiments containing a vehicle control (VC).
All concentrations were treated with triplicate replicates and kept as biological
triplicates throughout RNA purification and cDNA synthesis.
Once the cells have been treated for the appropriate time, the medium is removed
and 60µl PBS is used to wash the cells. This is removed and 60µl Trypsin is
added and incubated for 1 min at 37oC. 120µl ‘24 hour old’ medium is added to
the trypsin-cell mixture and then all the mixture is transferred to an eppendorf
tube. The tube is spun in a centrifuge for 5 minutes at 7000rpm at room
temperature. The medium is then removed leaving a cell pellet attached to the
bottom of the eppendorf tube ready for RNA purification.
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2.2.2 RNA purification
RNA was purified using Stratagene Absolute Miniprep Kit as per instructions
with the following alterations:
x ‘Appendix I: Protocol Modifications for small samples’ was followed
omitting the prefiltration step.
x 100ul Lysis buffer with 0.7µl B-ME was added to each sample before
100µl of 70% ethanol.
x 30µl of Elution buffer was warmed to 60oC then added to the fiber matrix.
x Purified RNA samples were aliquoted and stored at -20oC.
Gel Electrophoresis was carried out as a qualitative measure of the RNA present
in the samples. The gel consisted of 50 ml 1X TBE with 0.5g of agarose and 0.5
ml 10% SDS, which was melted and stored at 60oC till required. 1X TBE was
used as the buffer. Each lane contained 6µl sample RNA, 1µl 10X loading dye
and 3µl DEPC treated water. Unknown samples were compared against 1kb DNA
ladder, positive RNA control and a negative control. The samples were run for 90
minutes at 90 volts and 400mA. Visualisation of the RNA was done using a post-
staining technique of ethidium bromide staining for 25mins followed by a wash
with DEPC treated water for 20mins. A Bio-rad UV camera (Bio-rad Labs, USA)
was used to capture the DNA fragments using UV. Two bands are expected at 18s
and 28s to indicate good quality RNA.
Quanti-iT TM Ribogreen® RNA assay kit was used to estimate the RNA
concentrations in each sample and was also a useful way of checking the presence
of the RNA instead of using a gel which required a large volume of RNA to
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visualise it. A Wallac Victor2 plate reader (Perkin Elmer) was used to measure the
fluorescence from 0.5X Ribogreen dye. The plate reader was set at 485nm
excitation and 510nm emission. Each unknown sample contained 0.5µl 200X
Ribogreen dye, 2µl of RNA and 198µl 1X TE Buffer. A concentration curve was
made using known concentrations of 0, 20, 100, 500 and 1000ng/ml RNA which
allowed estimation of RNA in the unknown samples.
2.2.3 cDNA Synthesis
cDNA was produced using Stratascript QPCR cDNA Synthesis kit as per
instructions but with the following alterations:
x 1µl of oligo primers and 1µl of random primers along with 1µl Reverse
Transcriptase (RT) was added to 10µl Master Mix. Finally, 7µl of RNA
was added giving a final total of 20µl.
x A no RT and a no RNA control were made to check for contamination of
the reagents of cDNA or RNAs.
x A thermocycler (Techne ‘Genius’) was used, programmed for: 25oC for
5min, 42oC for 45mins, 95oC for 5min and then left at a storing
temperature of 4oC.
The cDNA was stored at -20oC. The cDNA concentration was measured using
Quanti-iT TM Picogreen® dsDNA assay kit as per instructions. A concentration
curve was used to estimate the concentration of cDNA in each sample, using a
linear curve with concentrations of 0, 10, 50, 100, 500 and 1000ng/ml. A Wallac
Victor2 plate reader (Perkin Elmer), which was set at 485nm excitation and
510nm emission, was used to measure the fluorescence produced by the Picogreen
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dye. Each sample contained 0.5X Picogreen dye, 5µl unknown cDNA and 195µl
TE Buffer. Picogreen dye required incubation for 2 minutes and was always
protected from light. All the samples collected from the 96 well plates were found
to have a cDNA concentration of 2-3ng/ml so purified water was added to each
sample to give a final concentration of 2ng/ml for each sample.
2.2.4 Quantitative Real-Time PCR
2.2.4.1 Methodology
Quantification of activation of the AhR requires a robust method of quantifying
induction of an AhR-dependent gene, in this case CYP1A1. Expression of the
CYP1A1 gene was achieved using Quantitative Real-Time PCR (RT-PCR). The
AhR and ȕ-Actin genes were also quantified to use as a control. This involved
developing a RT-PCR method which can be applied to several different AhR
agonists.
2.2.4.2 Probes and Primers
The probe and primer sequences for RT-PCR were obtained from Bell et al.
(2007). Table 2.2 shows the sequences of rat probes and primers used in RT-PCR
for CYP1A1, AhR and ȕ-Actin. Sequences are shown from 5’ to 3’, with Genbank
Accession number, reporter dye and quencher dye. Bell et al., (2007) found that
these three genes could be run in the same reaction and verified the identity and
reliability of the PCR products amplified by the primers (Bell et al., 2007).
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Gene Sequence GenBank Number Labels
CYP1A1 X00469
Primer (f) CCACAGCACCATAAGAGATACAAG
Primer (r) CCGGAACTAGTTTGGATCAC
Probe ATAGTTCCTGGTCATGGTTAACCTGCCAC FAM-BH1
AhR K02422
Primer (f) GCAGCTTATTCTGGGCTACA
Primer (r) CATGCCACTTTCTCCAGTCTTA
Probe TATCAGTTTATCCACGCCGCTGACATG HEX-BH1
ȕ-Actin V01217
Primer (f) CTGACAGGATGCAGAAGGAG
Primer (r) GATAGAGCCACCATCCACA
Probe CAAGATCATTGCTCCTCCTGAGCG ROX-BH2
Table 2.2: Sequences of Rat Probes and Primers - Forward (f) and Reverse (r) primers and
probes are indicated. Table shows gene name and sequence with Genbank Accession number,
reporter dye and quencher dye. Sequences are shown from 5’ to 3’. FAM: iscarboxy fluorescein,
HEX: hexachlorofluorescein and ROX: 5(6)-carboxy-X-rhodamine. The reporter dye is located at
the 5’ end of the probe, and the quencher dye, Black Hole-1 or -2 (BH1 or BH2), is found at the 3’
end. Sequences and information obtained from Bell et al. (Bell et al., 2007).
2.2.4.3 RT-PCR Efficiency
Development of an accurate RT-PCR method which can be applied to several
different AhR agonists was the first prerequisite. It was found initially that PCR
efficiencies for all three genes were ~60-90%, which is an anomalous result. One
hypothesis for this is too much probe. Therefore the effects of a reduction in probe
concentration from 200-600 nM to 100-300 nM, was tested using a TaqMan
Thermocycler (Mx4000). A concentration curve (1 to 3.91 x 10-3ng/ml) was
created. A final volume of 12.5µl buffer solution was added to each well
containing: 6.25µl master mix, A) 200-600 nM or B) 100-300 nM probes and
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200-600 nM of the primer pairs with 2ng cDNA. Mx4000 software was used to
calculate the PCR efficiency using a least mean squares curve fitting logarithm.
Results concluded that a lower concentration of probe gave improvement of both
correlation coefficient and slope, with efficiency of ~100-120% (See results
3.1.2.2). Critical analysis of PCR efficiency is thus a prerequisite for accurate
data.
2.2.4.4 Measurement of CYP1A1 induction
Real-time PCR (RT-PCR) was done using a TaqMan Thermocycler (Mx4000).
Each well contained 2µl of 2ng/ml cDNA from each unknown sample made to a
final volume of 12.5µl with 10.5µl RT-PCR mixture (See table 2.3).
Table 2.3: Quantities of reagents used for each sample – Table shows the required volume of
each probe and primer that makes up the correct proportions for the RT-PCR mixture. 2µl of 2ng
sample cDNA will be added to this mixture. The initial concentration of all the primers and probes
used was 10 µM and 5 µM, respectively (Diluted to required concentration using TE Buffer pH
7.5).
Component Each Sample
Master mix 6.25µl
CYP1A1 Forward 0.25µl
Reverse 0.25µl
Probe 0.5µl
ȕ-Actin Forward 0.5µl
Reverse 0.5µl
Probe 1µl
AhR Forward 0.75µl
Reverse 0.5µl
Probe 1.5µl
Richard Wall
34
All reactions were done in duplicate (Duplicates of biological triplicates for each
concentration tested). During each experiment, five separate controls were run
simultaneously using the same RT-PCR mixture (Figure 2.3). Firstly, a 10 nM
TCDD sample and an untreated sample, both from the same batch, were run
allowing comparison between experiments. Secondly, internal controls were run
for each individual experiment consisting of a no template control (NTC) to check
for contamination in the RT-PCR master mix, a No RT and No RNA control to
check contamination during the cDNA synthesis stage. A 40 cycle programme of
20 seconds at 95oC and 90 seconds at 58oC was used. The mRNA levels for each
gene were calculated using PCR cycling threshold (Ct) values generated by the
Mx4000 software. The Ct values for the control genes should be relatively similar
so can be used to normalise the CYP1A1 RNA.
2.2.5 Qbase and Graph Software
Although the cDNA was normalized before RT-PCR it was still necessary to
normalize the CYP1A1 RNA against both ȕ-Actin and AhR RNA for increased
accuracy. This was done using Qbase software (Hellemans et al., 2007) which
gives relative values of CYP1A1 RNA in comparison to levels of reference genes,
ȕ-Actin and AhR. To ensure accurate assessment of the results produced by
Qbase, two quality measures are calculated. Firstly, the coefficient of variation
(CV) of the normalized relative quantities, also known as the gene evaluation
value, with a low value indicating high stability. Secondly, the geNorm value
which measures the stability of the genes, confirming that they are stably
expressed. This allows identification of the best genes to use for normalisation,
which in these assays will always be a combination of both AhR and ȕ-Actin.
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With the exception of initial method calibration, data will be assessed based on
the gene evaluation value alone.
The relative values for CYP1A1 RNA are then converted into percentages with
the largest value denoted as 100%. In the instance of the partial agonism
experiments, the curve, which was generated using Prism 5 software, had its
lower limit set to the percentage of the maximal response of the antagonist in the
absence of TCDD. This was generally about 15% of the induction of the maximal
response of the agonists. Graphs were generated using a non linear regression
curve with the settings ‘log[agonist] vs. normalised response’. The Prism software
also calculated the EC50 and the 95% Confidence interval allowing comparison
between partial agonism and control curves. Normalised CYP1A1 RNA data was
plotted alongside the relevant controls which could include; agonist/antagonist
only control (AC), 10 µM TCDD only control (TC) and vehicle control (VC).
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3. Results
3.1 Cell Growth Curve
The growth of H4-IIE cells was characterised so accurate estimation of
confluence could be conducted. Therefore, a cell growth curve was generated.
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Figure 3.1: Cell Growth Curve for H4-IIEC3 – Cells were cultured in a 96 well plate with
180µl medium which was changed after 96 hours. On each day, cells were washed with PBS,
tripsinised and counted with a haemocytometer as described in method 2.2.1.1. Each point equals
mean ± S.D. of 3 replicates.
Figure 3.1 shows the H4-IIEC3 cell growth curve over a period of 8 days.
Confluence was reached after 6 days with concentrations of ~2 x 105¢/well.
3.2 CYP1A1 Induction - Method Calibration
3.2.1 Methodology
Quantification of activation of the AhR requires a robust method of quantifying
induction of an AhR-dependent gene, in this case CYP1A1. This involves
developing a RT-PCR method which can be applied to several different AhR
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agonists. Initially, a dose-response curve was produced for TCDD which allowed
construction and optimisation of a method of measurement of AhR activation.
3.2.3 Method calibration using TCDD
3.2.3.1 RNA and cDNA
H4-IIEC3 Rat Liver cells were treated with TCDD (100 fM- 10 nM) for 4 hours.
RNA was purified using Absolutely RNA Miniprep kit (Stratagene) as described
(section 2.2.2). Quality of RNA was assayed using a 1X TBE agarose gel, post
stained with ethidium bromide and photographed with Biorad UV camera (Figure
3.2).
Figure 3.2: Agarose gel showing RNA - Cells were treated with and without TCDD for 4 hours;
RNA was then purified as mentioned in the method (section 2.2.2). Samples were run for 90 mins
(90 volts/max. 400mA). Gel was post stained with ethidium bromide. A digital image of the gel
under UV illumination is shown. (Lane 1) 1kb DNA ladder, (Lane 2) positive control, (Lane 5)
negative control, (Lane 3) untreated RNA and (Lane 4) 10 nM TCDD treated RNA.
Figure 3.2 shows bands at 18s and 28s confirming the quality of the purified
RNA. RNA from the samples was then quantitated using a Ribogreen RNA
quantition Kit. A standard curve was produced with known RNA concentrations
1
2
3
4
5
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allowing a comparative measure of RNA in the unknown samples (see method,
section 2.2.2). RNA yield was typically 15-20 µg per well. RNA quality and
quantity checks were only performed during method calibration and initial TCDD
dose-response curve. cDNA was synthesised using AffinityScript QPCR cDNA
Kit (see method, section 2.2.3). Quantitation of cDNA concentration was done
using Picogreen cDNA quantitation Kit. A standard curve was used to measure
cDNA quantities in each sample during every experiment. Yield was typically 1-3
µg cDNA per reaction.
3.2.2.2 Real Time-PCR
The induction of CYP1A1 RNA was chosen as it is one of the most sensitive
measures of AhR activation. It is necessary to determine the efficiency of PCR, as
this has a substantial effect on estimation of RNA amount. In order to test this,
several standard curves were produced with various concentrations of probe. Each
well contained the master mix (Table 2.2) with probe concentrations changed
accordingly, and various concentrations of cDNA.
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Figure 3.3: PCR efficiency for CYP1A1, ȕ-Actin and AhR, (A) 200-600 nM Probe and (B)
100-300 nM Probe. A concentration gradient was constructed from a known cDNA concentration.
RT-PCR was conducted as mentioned in method (section 2.2.4). The initial quantity of input
cDNA is shown on the x-axis as a relative amount, and the Ct for each dilution is shown on the Y-
axis, for n=3 replicates. The fit of the data to the line was determined by r2 analysis, and the
efficiency of PCR was determined from the slope of the line.
Figure 3.3A shows the amount of RNA measured (Ct) as a function of input
cDNA; this analysis shows a poor fit of the data to the line of best fit (Figure
3.3A), and efficiency of PCR is ~60-105%, an anomalous result. The initial
quantity of input cDNA is shown on the x-axis as a relative amount, and the Ct for
each dilution is shown on the Y-axis, for n=3 replicates. The fit of the data to the
line was determined by r2 analysis, and the efficiency of PCR was determined
from the slope of the line. The r2 values for figure 3.3A were 0.982, 0.838 and
0.840 for CYP1A1, ȕ-Actin and AhR, respectively. Figure 3.3B demonstrates the
effect of a reduction in probe concentration from 200-600 nM to 100-300 nM,
with improvement of both correlation coefficient and slope, with efficiency ~100-
115%. The r2 values for figure 3.3B were 0.997, 0.998 and 0.999 for CYP1A1, ȕ-
B
pe
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Actin and AhR, respectively, providing a far bet fit than figure 3.3A. Analysis of
PCR efficiency is thus a prerequisite for accurate data. Once PCR efficiency was
improved, it was possible to measure the induction of CYP1A1 RNA by TCDD.
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Figure 3.4: RT-PCR Amplification plots - (A) CYP1A1 (B) ȕ-Actin and (C) AhR, when dosed
with various concentrations of TCDD for 4hrs. RNA was purified, cDNA was synthesised and RT-
PCR was run as demonstrated in the method (section 2.2.4). All genes were run in same well. The
Y-axis shows the fluorescence at each Ct, for n=mean of 6 replicates (duplicates of 3 biological
replicates).
Figure 3.4 shows the amplification plots for CYP1A1 and ȕ-Actin when dosed
with various concentrations of TCDD for 4 hours. The input cDNA was first
normalized thus giving 2ng of cDNA per sample. Figure 3.4B and 3.4C shows
that the control genes, ȕ-Actin and AhR were unaffected by the TCDD treatment.
Qbase was used to analyse the data derived from RT-PCR analysis. Qbase
normalizes the expression of CYP1A1 against the reference genes, AhR and ȕ-
Actin. The reference gene expression should be within two-fold, indicating
accurate sample preparation and quantitation. The amplification plots in figure 3.4
show the mean of 6 replicates with the average standard deviation = ± 0.8.
C
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3.2.2.3 Dose-response curve
RT-PCR was used to measure CYP1A1 induction with the results normalised to
relative quantities using Qbase. Qbase calculates two quality measures, firstly, the
coefficient of variation (CV). The CV, also known as the gene evaluation value,
for AhR and ȕ-Actin was 16% and 19%, respectively, indicating high stability.
Secondly, the geNorm value, which measures the stability of the genes
(Hellenmans et al., 2006): 0.37, confirming that they are stably expressed; further
work will only look at the gene evaluation value (see method, section 2.2.5).
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Figure 3.5: Induction of CYP1A1 RNA by TCDD. H4-IIEC3 cells were treated with the
indicated dose of TCDD, or vehicle control, for four hours, as described in materials and methods
section 2.2.1. RNA was isolated from cells, and analysed for CYP1A1, ȕ-Actin and AhR RNAs by
real-time PCR, as described in section 2.2. CYP1A1 RNA was normalised using Qbase (section
2.2.5) against ȕ-Actin and AhR RNAs, and then normalised to the maximum response, which is
shown as 100%. The response of CYP1A1 against log dose is shown, and each point represents
n=3 biological replicates, ± S.D. VC: Vehicle control.
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The last phase was to produce a dose-response curve using the normalized relative
quantities (NRQ) of CYP1A1 RNA calculated by Qbase. The EC50 and the 95%
confidence intervals for the EC50 were determined using a non linear regression
curve with the settings ‘log[agonist] vs. normalised response’. Figure 3.5 shows
the response of CYP1A1 against the dose. The plot of response of CYP1A1
against log dose yields an EC50 = 34 pM, 95% Confidence interval = 29 pM - 38
pM. The dose/response relationship shows a classical curve with a small 95% CI
due to the use of multiple concentrations. Replicate EC50 estimates were similar in
four repeats (Figure 3.7). CYP1A1 (Figure 3.4A) was induced by ~150-fold over
control (10 nM against vehicle) with high induction indicating large signal to
noise ratio and accurate induction parameters.
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Figure 3.6: Confirmation of no induction by AhR or ȕ-Actin RNA by TCDD. H4-IIEC3 cells
were treated with the indicated dose of TCDD, or vehicle control, for 4 hours, as described in
section 2.2.1. RNA was isolated from cells, and analysed for CYP1A1, ȕ-Actin and AhR RNAs by
real-time PCR, as described in section 2.2. The two reference genes have been compared against
maximal normalised value of CYP1A1 RNA. The response of ȕ-Actin and AhR against log dose is
shown, and each point represents n=3 biological replicates, ± S.D. VC: Vehicle control.
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Figure 3.6 demonstrates that the reference genes, ȕ-Actin and AhR, were
unaffected by the treatment even at the maximum concentrations of TCDD.
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Figure 3.7: Induction of CYP1A1 RNA by TCDD – Comparisons of Four Separate TCDD
D/R Curves - H4-IIEC3 cells were treated with the indicated concentrations of TCDD for 4 hours.
The graph shows four curves taken from each experiment in section 3.2. Cell treatment, RNA
isolation and RT-PCR analysis was as described for Figure 3.5. The normalised response of
CYP1A1 against log dose is shown, and each point represents n=3 biological replicates, ± S.D.
VC: Vehicle control.
Figure 3.7 compares four TCDD only dose-response curves taken from various
assays in section 3.2. The curves have a similar shape with considerable
overlapping of means and 95% confidence intervals. This gave an average EC50 of
35 pM (S.D. = ± 5.8 pM). The average of the Qbase derived gene evaluation
values were ~25% and ~33% for ȕ-Actin and AhR, respectively. This allows
comparison of data between assays as the EC50 of each TCDD curve is similar and
provides evidence that each repeat is reproducible and hence reliable.
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3.3 Partial Agonism Assays
3.3.1 Methodology
The ability of known AhR agonists to act as partial agonists of the induction of
CYP1A1 was evaluated by determining if these chemicals could antagonise the
induction of CYP1A1 RNA by TCDD in H4-IIEC3 cells, as previously reported.
Five different AhR agonists and one AhR antagonist were evaluated. The
approach taken was to determine the amount of test chemical that would give
approximately 15% of maximal induction of CYP1A1 RNA; this concentration of
chemical was then used to determine whether it could antagonise the induction of
CYP1A1 RNA by TCDD.
3.3.2 3-Methylcholanthrene (3-MC)
The induction of CYP1A1 RNA by 3-Methylcholanthrene (3-MC) was examined.
Cells were treated with 3-MC (1 µM to 1 pM) and compared with a vehicle
control (VC). The reference genes had gene evaluation values of 46% and 39%
for ȕ-Actin and AhR, respectively. The data was plotted into a dose-response
curve (figure 3.8) which has an EC50 = 2.3 nM (95% Confidence interval = 1.3
nM to 3.8 nM). The concentration at which 15% of maximal response was
reached was 300 pM. Thus this experiment robustly estimates the agonist potency
of 3-MC.
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Figure 3.8: Induction of CYP1A1 RNA by 3-MC - H4-IIEC3 cells were treated with the
indicated dose of 3-MC, or vehicle control, for four hours, as described in materials and methods
section 2.2.1. RNA was isolated from cells, and analysed for CYP1A1, ȕ-Actin and AhR RNAs by
real-time PCR, as described in section 2.2. CYP1A1 RNA was normalised using Qbase (section
2.2.5) against ȕ-Actin and AhR RNAs, and then normalised to the maximum response, which is
shown as 100%. The response of CYP1A1 against log dose is shown, and each point represents
n=3 biological replicates, ± S.D. VC: Vehicle control.
In order to determine whether 3-MC could act as an antagonist, cells were treated
with various concentrations of TCDD (100 nM to 1 pM) in the presence or
absence of 300 pM 3-MC. This was compared to an agonist only control (AC) and
vehicle control (VC).
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Figure 3.9: Induction of CYP1A1 RNA by TCDD with and without 300 pM 3-MC - H4-IIEC3
cells were treated with the indicated concentrations of TCDD, in the presence or absence of 300
pM 3-MC. Cell treatment, RNA isolation and RT-PCR analysis was as described for Figure 3.8.
The normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D. VC: Vehicle control. AC: Agonist only control.
Figure 3.9 shows TCDD in the presence and absence of 300 pM 3-MC. The
results show that the response to 3-MC only control (AC) is approximately 15%
of maximal induction. The gene evaluation values were 17% and 19% for AhR
and ȕ-Actin, respectively: this shows that there is little variation in the
measurements of AhR and ȕ-Actin, thereby giving confidence in the RT-PCR.
The EC50 of TCDD with 3-MC was 49 pM (95% confidence interval = 19 pm-126
pM) compared with an EC50 of 50 pM (95% Confidence interval = 19 pM to 133
pM) for TCDD alone: these are not significantly different, thus 3-MC has no
detectable antagonist activity in this assay.
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3.3.3 2,3,7,8-Tetrachlorodibenzofuran (TCDF)
The induction of CYP1A1 RNA by 2,3,7,8-Tetrachlorodibenzofuran (TCDF) was
analysed. H4-IIEC3 cells were treated with various concentrations of TCDF or
vehicle control (VC) to characterise the induction of CYP1A1 RNA. AhR and ȕ-
Actin gave gene evaluation values of 102% and 65%, respectively. An EC50 of 5.8
nM (95% confidence interval of 2.8 nM to 11 nM) was estimated for induction of
CYP1A1 RNA (figure 3.10). This gave a concentration of 300 pM TCDF (15% of
maximal response) which was then added to TCDD treated cells (various
concentrations between 10 nM and 100 fM).
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Figure 3.10: Induction of CYP1A1 RNA by TCDF - H4-IIEC3 cells were treated with the
indicated concentrations of TCDF. Cell treatment, RNA isolation and RT-PCR analysis was as
described for Figure 3.8. The normalised response of CYP1A1 against log dose is shown, and each
point represents n=3 biological replicates, ± S.D. VC: Vehicle control.
The dose-response curve for TCDD in the presence of 300 pM TCDF is shown in
figure 3.11 which has been compared with a TCDD only curve. A 300 pM TCDF
Richard Wall
49
only control (AC) and a vehicle control (VC) were also run in the same
experiment. Gene evaluation values were 51% and 38% for AhR and ȕ-Actin,
respectively. Cells exposed to TCDF alone induced CYP1A1 RNA to 39.5% of
maximal induction however it is still possible to use the data to compare the EC50
for each curve.
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Figure 3.11: Induction of CYP1A1 RNA by TCDD with and without TCDF - H4-IIEC3 cells
were treated with the indicated concentrations of TCDD, in the presence or absence of 300 pM
TCDF. Cell treatment, RNA isolation and RT-PCR analysis was as described for Figure 3.8. The
normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D. VC: Vehicle control. AC: Agonist only control.
The results for TCDD with 300 pM TCDF show that the background is
approximately 40% induction of the possible antagonist, TCDF, however when
the EC50 of TCDD with TCDF (EC50 = 104 pM, 95% CI = 20 pM-535 pM) is
compared with TCDD alone (EC50= 65 pM, 95% CI = 39 pM-107 pM) there is no
significant difference with complete crossover of the 95% confidence intervals.
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Therefore it can be concluded that TCDF exhibited no detectable antagonistic
properties in this experiment.
3.3.4 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF)
2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) was added to cells for 4 hours and
the induction of CYP1A1 RNA was measured to locate the concentration of
PeCDF which gives 15% of the maximal response. Gene evaluation values were
48% and 40% for AhR and ȕ-Actin, respectively.
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Figure 3.12: Induction of CYP1A1 RNA by PeCDF - H4-IIEC3 cells were treated with the
indicated concentrations of PeCDF. Cell treatment, RNA isolation and RT-PCR analysis was as
described for Figure 3.8. The normalised response of CYP1A1 against log dose is shown, and each
point represents n=3 biological replicates, ± S.D. VC: Vehicle control.
Figure 3.12 shows the dose-response curve for PeCDF with the EC50 as 2.2 nM
(95% CI = 1.4 nM to 3.4 nM) and reveals the concentration for 15% of maximal
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response which was 1 nM. H4-IIEC3 cells were then treated with various
concentrations of TCDD (10 nM – 100 pM) with the addition of 1 nM PeCDF. A
1 nM PeCDF only control (AC) and a vehicle control (VC) were also included.
The TCDD with PeCDF dose-response curve was compared with a TCDD alone
curve (Figure 3.13) and shows that the background is 14% induction of the
possible antagonist, PeCDF.
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Figure 3.13: Induction of CYP1A1 RNA by TCDD with and without 1 nM PeCDF - H4-
IIEC3 cells were treated with the indicated concentrations of TCDD, in the presence or absence of
1 nM PeCDF. Cell treatment, RNA isolation and RT-PCR analysis was as described for Figure
3.8. The normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D. VC: Vehicle control. AC: Agonist only control.
Normalised quantities of AhR and ȕ-Actin reference genes had gene evaluation
values of 21% and 20%, respectively. The EC50 of TCDD with PeCDF was 24 pM
(95% CI = 13 pM-46 pM) which was compared against TCDD alone (EC50= 34
pM, 95% CI = 18 pM-63 pM) and was found to be significantly similar, with
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considerable crossover of the 95% confidence intervals of the EC50s. The results
have demonstrated that PeCDF has no antagonist properties in this experiment.
3.3.5 3,3’,4,4‘,5- Pentachlorobiphenyl (PCB 126)
The induction of CYP1A1 RNA by 3,3’,4,4‘,5- Pentachlorobiphenyl (PCB 126)
was measured. Cells were treated for 4 hours with various concentrations of PCB
126 (100 nM to 1 pM) and compared with a vehicle control (VC).
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Figure 3.14: Induction of CYP1A1 RNA by PCB 126 - H4-IIEC3 cells were treated with the
indicated concentrations of PCB 126. Cell treatment, RNA isolation and RT-PCR analysis was as
described for Figure 3.8. The normalised response of CYP1A1 against log dose is shown, and each
point represents n=3 biological replicates, ± S.D. VC: Vehicle control.
Figure 3.14 shows dose compared with the normalised induction of CYP1A1 by
PCB 126 which was derived from the normalisation of CYP1A1 RNA by Qbase
(gene evaluation values of 14% and 12% for ȕ-Actin and AhR, respectively). The
curve shows the EC50 which was 765 pM (95% CI = 645 pM-907 pM) and allows
identification of the concentration of PCB 126 which gives 15% of maximal
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induction which was 100 pM. Cells were then treated with various concentrations
of TCDD (10 nM to 100 fM) in the presence of 100 pM PCB 126 for 4 hours and
compared with a 100 pM PCB 126 only control (AC) and a vehicle control (VC).
CYP1A1 RNA was then normalised using Qbase software against the reference
genes, ȕ-Actin and AhR (gene evaluation values of 48% and 68%, respectively).
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Figure 3.15: Induction of CYP1A1 RNA by TCDD with and without PCB 126 - H4-IIEC3
cells were treated with the indicated concentrations of TCDD in the presence and absence of 100
pM PCB 126. Cell treatment, RNA isolation and RT-PCR analysis was as described for Figure
3.8. The normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D. VC: Vehicle control. AC: Agonist only control.
Figure 3.15 shows the induction of CYP1A1 by TCDD in the presence and
absence of 100 pM PCB 126 compared with a 100 pM PCB 126 only control
(AC) and a vehicle control (VC). The EC50 of TCDD with PCB 126 was 66 pM
(95% CI = 31 pM-139 pM) which was compared with TCDD alone (EC50 = 34
pM, 95% CI = 22 pM-51 pM). This comparison shows that there is no significant
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difference between the EC50s and demonstrates that in this assay PCB 126 has no
antagonistic effects in the presence of TCDD.
3.3.6 2-(4-Amino-3-Methylphenyl)-Benzothiazole (DF 203)
Previous literature (Bazzi, 2008; Chau et al., 2000; Elferink et al., 2003; Loaiza-
Perez et al., 2002) has described 2-(4-Amino-3-Methylphenyl)Benzothiazole (DF
203) as having agonist properties but with data collected by Bazzi (2008), the
potential antagonistic effects should also be investigated. The induction of
CYP1A1 RNA by DF 203 shown in figure 3.16 demonstrates that the compound
has agonist properties. Cells were treated with various concentrations of DF 203
(100 µM to 1 nM) which was compared with a vehicle control (VC).
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Figure 3.16: Induction of CYP1A1 RNA by DF 203 - H4-IIEC3 cells were treated with the
indicated concentrations of DF 203. Cell treatment, RNA isolation and RT-PCR analysis was as
described for Figure 3.8. The normalised response of CYP1A1 against log dose is shown, and each
point represents n=3 biological replicates, ± S.D. VC: Vehicle control.
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Figure 3.16 shows the induction of CYP1A1 RNA by DF 203 which has an EC50
of 1.5 µM (95% CI = 1.2 µM-1.8 µM). Gene evaluation values of 13% and 13%
for ȕ-Actin and AhR, respectively. The curve also allows location of the
concentration that gives 15% of maximal induction which was estimated, based
on the curve, to be 300 nM. Cells were then treated with various concentrations of
TCDD in the presence of 300 nM DF 203 which was compared with a 300 nM DF
203 only control (AC) and a vehicle control (VC). ȕ-Actin and AhR gene
evaluation values were 19% and 21%, respectively.
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Figure 3.17: Induction of CYP1A1 RNA by TCDD with and without 300 nM DF 203 - H4-
IIEC3 cells were treated with the indicated concentrations of TCDD in the presence and absence of
300 nM DF 203. Cell treatment, RNA isolation and RT-PCR analysis was as described for Figure
3.8. The normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D. VC: Vehicle control. AC: Agonist only control.
Figure 3.17 shows the induction of CYP1A1 RNA by TCDD in the presence of
300 nM DF 203 (EC50= 24 pM, 95% CI = 7.2 pM-79 pM). This was compared
with TCDD alone (EC50= 34 pM, 95% CI = 18 pM-63 pM). It can be seen from
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the results that 15% of maximal induction by 300 nM DF 203 was not reached by
the agonist only control or the lower concentrations of TCDD with DF 203 and
there is no significant difference between EC50s. Due to this a second dose-
response curve for TCDD in the presence of DF 203 was produced but using a
larger concentration of DF 203. In the second dose-response curve, a
concentration of 1 µM DF 203 was added to cells treated with various
concentrations of TCDD (10 nM to 100 fM).
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Figure 3.18: Induction of CYP1A1 RNA by TCDD with and without 1 µM DF 203 - H4-
IIEC3 cells were treated with the indicated concentrations of TCDD in the presence and absence of
1 µM DF 203. Cell treatment, RNA isolation and RT-PCR analysis was as described for Figure
3.8. The normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D. VC: Vehicle control. AC: Agonist only control.
Reference genes, ȕ-Actin and AhR, had gene evaluation values of 11% and 10%,
respectively. Figure 3.18 shows that there is a background of 54% induction in the
presence of 1 µM DF 203. The EC50 of TCDD with DF 203, which was 726 pM
(95% CI = 69 pM-7.6 nM), was significantly different from that of TCDD alone
Richard Wall
57
(EC50 = 34 pM, 95% CI = 18 pM-63 pM) and there is no crossover of 95%
confidence intervals. It can be seen that in the presence of DF 203, the TCDD
induction curve moves to the right demonstrating that DF203 has both agonistic
and antagonistic properties.
3.3.7 CH 223191
A known antagonist, 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-
tolylazo-phenyl)-amide (CH 233191) has no reported agonist properties. Kim et
al. (2006), and this paper looked to estimate concentrations of CH 223191 that
would provide antagonism in the presence of TCDD. Using data from the study
by Kim et al. (2006), two concentrations of antagonist were determined, 300 nM
and 10 µM. As in previous assays, cells were treated with various concentrations
of TCDD (10 nM to 100 fM) however; in this instance they were also compared
with a 10 µM TCDD only control to confirm maximal response. An antagonist
only control (10 µM CH 223191) was also performed to confirm that the
compound had no agonist properties. In figure 3.19, 300 nM CH 223191 was
added to various concentrations of TCDD and compared with a 10 µM TCDD
(TC), an antagonist only control (AC) and a vehicle control (VC). Gene
evaluation values of 58% and 41%, for AhR and ȕ-Actin.
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Figure 3.19: Induction of CYP1A1 RNA by TCDD with and without 300 nM CH-223191 -
H4-IIEC3 cells were treated with the indicated concentrations of TCDD in the presence and
absence of 300 nM DF 203. Cell treatment, RNA isolation and RT-PCR analysis was as described
for Figure 3.8. VC: Vehicle control, AC: Antagonist only control, TC: 10 µM TCDD only control.
The normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D.
Figure 3.19 shows various concentrations of TCDD in the presence and absence
of 300 nM CH 223191. The EC50 of TCDD with CH 223191 was 44 pM (95% CI
= 28 pM - 70 pM) which was compared with TCDD alone (EC50 = 29 pM, 95%
CI = 21 pM - 39 pM). The data shows that there is no difference between EC50s
with the 95% CI from each curve overlapping considerably. It is therefore
possible to deduce that at this concentration of antagonist, CH 223191 has no
effect on the induction of CYP1A1 by TCDD. One possibility is that a larger
concentration of CH 223191 is required to obtain measurable antagonism. In the
next assay, 10 µM of CH 223191 was added to TCDD treated cells (various
concentrations). This was also compared with a 10 µM TCDD only control (TC),
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antagonist only control (AC) and a vehicle control (VC). Gene evaluation values
of 88% and 53% were obtained for AhR and ȕ-Actin, respectively.
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Figure 3.20: Induction of CYP1A1 RNA by TCDD with and without 10 µM CH-223191 - H4-
IIEC3 cells were treated with the indicated concentrations of TCDD in the presence and absence of
10 µM CH 223191. Cell treatment, RNA isolation and RT-PCR analysis was as described for
Figure 3.8. VC: Vehicle control, AC: Antagonist only control, TC: 10 µM TCDD only control.
The normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D.
It can be seen in figure 3.20 that CH 223191 has inhibited the induction of
CYP1A1 by TCDD by approximately >100 fold. Unfortunately, it isn’t possible
to derive an accurate and reliable EC50 from this data set, so comparison is subject
to considerable inaccuracy. However, there is a large difference between curves,
which is likely to be significant, although this can’t be supported quantitatively.
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3.4 The Effect of Time of Exposure on Induction of CYP1A1 RNA
3.4.1 Methodology
The standard induction assay used in this thesis exposes cells to chemical
treatment for only four hours, on the basis that this minimises the effect of
metabolism on the chemical. However, the effect of exposure time on induction of
CYP1A1 has not been carefully examined. The hypothesis that longer exposure
times would increase the apparent EC50 (decrease the potency) of metabolically-
labile chemicals, whilst not affecting the EC50 of metabolically-resistant
chemicals, was tested. RT-PCR was used (Section 3.1) with cells also been treated
for 24 hours. Induction of CYP1A1 RNA by 3-MC was measured for both 4 and
24 hours and compared with TCDD which was also measured at 4 and 24 hours.
3.4.2 3-Methylcholanthrene
The induction of CYP1A1 RNA by 3-Methylcholanthrene (3-MC) was measured
where cells were treated for 4 and 24 hours. Various concentrations (10 µM - 1
pM 3-MC) were compared against vehicle controls (VC) (controls were treated
for either 4 or 24 hours, giving two sets). Gene quality evaluation values were
39% and 46% at 4 hours and 15% and 13% at 24 hours for AhR and ȕ-Actin,
respectively. The normalized response data was then plotted against concentration
(Figure 3.21).
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Figure 3.21: Induction of CYP1A1 RNA by 3-MC at 4 and 24 hours - H4-IIEC3 cells were
treated with the indicated dose of 3-MC, or vehicle control, for 4 or 24 hours, as described in
materials and methods section 2.2.1. RNA was isolated from cells, and analysed for CYP1A1, ȕ-
Actin and AhR RNAs by real-time PCR, as described in section 2.2. CYP1A1 RNA was
normalised using Qbase (section 2.2.5) against ȕ-Actin and AhR RNAs, and then normalised to
the maximum response, which is shown as 100%. Each curve has been individually normalised
and then compared. The response of CYP1A1 against log dose is shown, and each point represents
n=3 biological replicates, ± S.D. VC: Vehicle control.
There is a significant difference in the potency of 3-MC between 4 and 24 hours.
The EC50 after four hours treatment was 2.3 nM (95% CI = 1.3 nM-3.8 nM) and
94 nM (95% CI = 74 nM-120 nM) after 24 hours treatment. In agreement with the
prior hypothesis, larger concentrations are required for maximal response at 24
hours in comparison to 4 hours, and this effect is substantial, with 3-MC being
~40-fold less potent at the later time point.
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3.4.3 Tetrachlorodibenzo-p-dioxin
The induction of CYP1A1 RNA by TCDD when treated for 4 and 24 hours was
analysed in order to establish whether metabolically stable compounds show a
constant potency with time. Concentrations between 10 nM and 100 fM were used
each time and compared against a vehicle control (VC). Figure 3.22 shows the
induction of CYP1A1 RNA at each time. At 4 hours the gene evaluation values
were 9% and 8% for ȕ-Actin and AhR, respectively and at 24 hours they were
13% and 13%.
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Figure 3.22: Induction of CYP1A1 RNA by TCDD at 4 and 24 hours - H4-IIEC3 cells were
treated with the indicated concentrations of TCDD in the presence and absence of 1 µM DF 203.
Cell treatment, RNA isolation and RT-PCR analysis was as described for Figure 3.20. The
normalised response of CYP1A1 against log dose is shown, and each point represents n=3
biological replicates, ± S.D. VC: Vehicle control.
At 4 hours the EC50 was 34 pM (95% = 18 pM-63 pM) and at 24 hours the EC50
was 149 pM (95% CI = 120 pM-185 pM), a difference of ~4 fold (Figure 3.22).
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This demonstrates a significant increase in concentration required for induction
between 4 and 24 hours, although this ~4-fold difference is smaller than the ~40-
fold difference for 3-MC. These results demonstrate that time of exposure of cells
to compound is a key variable that affects potency estimations.
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4. Discussion
4.1 Measurement of CYP1A1
4.1.1 The Use of the H4-IIE Bioassay
Induction of CYP1A1 alone does not imply a toxic effect but instead works in
parallel with other responses responsible for those toxic effects (Whyte et al.,
2004). Therefore care is required when using CYP1A1 induction to estimate the
toxicity of a compound even though previous evidence confirms the parallel
relationship between CYP1A1 induction and toxic effects (Safe, 1990). The H4-
IIE bioassay method is useful for estimating the toxicity of HAHs in organisms
but not so well for PAHs, as they are easily metabolised and don’t bioaccumulate
to the extent of HAHs. H4-IIE cells have low basal Aryl hydrocarbon hydroxylase
(AHH) and CYP1A1 levels (Benedict et al., 1973). The main advantage of H4-IIE
cell models is that the treatment won’t be effected by metabolism. Further
advantages of in vitro models, with regards to in vivo models, are the high
through-put and elimination of inter-animal differences.
4.1.2 CYP1A1 mRNA vs. EROD Enzyme Analysis
Quantitative analysis of the activation of AhR, through measurements of CYP1A1
RNA, is critically dependent on the methodology for RNA measurement.
CYP1A1-associated enzymes, Ethoxyresorufin-O-deethylase (EROD) and Aryl
hydrocarbon hydroxylase (AHH) are induced by TCDD-like compounds
(Kennedy 1993). EROD activity has historically been used as a measure of AhR
activation (; Clemons et al., 1997, 1998; Hilscherova et al., 2001; Peters et al.,
2004; Sanderson et al., 1996; Schmitz et al., 1995; Silkworth et al., 2005). EROD
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activity measures the rate of CYP1A1-mediated deethylation of 7-ethoxyresorufin
(7-ER) leading to the production of highly-fluorescent resorufin, measured using a
plate reader. The method replaced AHH activity in the mid 1980’s due to the
increased safety and economy of EROD, compared with AHH measurement. The
system also has a greater efficiency and is much more cost effective (Whyte et al.,
2004). PCR technology has allowed the measurement of CYP1A1 RNA which
provides a more sensitive measurement of AhR activation compared with EROD
(Vanden Heuvel et al., 1994). Research has shown that certain PCBs inhibit the
EROD enzyme-substrate reaction making mixture experiments impossible to
accurately measure, and illustrating the generic pitfall that enzyme activity
measurement can be a flawed measure of AhR activation (Petrulis et al., 1999).
CYP1A1 RNA induction is one of the most potent effects of AhR activation so
would be expected to give both the most accurate and most sensitive results.
Measurement of resorufin requires that the cells are treated for longer periods of
time to allow translation of the enzymes. Longer periods of treatment can lead to
the metabolism of some compounds, including 3-MC (Riddick et al., 1994) and
TCDF (Clemons et al., 1997). In this thesis a method of measuring the induction
of CYP1A1 was calibrated using RT-PCR. Several variables that affect accurate
measurement of CYP1A1 RNA were identified and optimised, yielding a
methodology with considerable statistical power for the determination of the
potency of an agonist for inducing CYP1A1 RNA. Statistical power is a
prerequisite for detecting small differences in potency. Such quantitative
measurement of induction potency enables the application of a variety of
pharmacological tools to investigate the nature of agonism.
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4.1.3 Reliability of Data
Several mechanisms were put in place to ensure the reliability of the data.
Initially, the cDNA yield was normalised using Picogreen (Quanti-iT TM
Picogreen® dsDNA assay kit). During PCR, three different controls confirmed
that there was no DNA contamination, in both cDNA synthesis and RT-PCR
analysis. Also during RT-PCR analysis, controls of 10 µM TCDD and vehicle
were also run demonstrating no substantial differences between assays. The
induction of CYP1A1 RNA was normalised against two reference genes, ȕ-Actin
and AhR, which were unaffected by any of the treatments used. Measurement of
these reference genes was conducted on every sample alongside CYP1A1 as a
way to normalise the levels of CYP1A1 RNA. The results of figure 3.5 show that
neither of the reference genes, AhR and ȕ-Actin, were affected by the vehicle or
various concentrations of TCDD which proves that the cDNA used was of good
quality and equal concentration within each sample.
The quality of the reference genes used for normalisation of CYP1A1 RNA was
evaluated by Qbase, with the more reliable genes allocated a lower gene
evaluation value. The gene evaluation value indicates how stably expressed the
gene is with values of <50% considered reliable and higher values indicating less
reliable results (Hellenmans et al., 2007). The mean gene evaluation values for
TCDD in this study were ~25% and ~33% for ȕ-Actin and AhR, respectively,
with similar values seen throughout the study with only a few exceptions, such as
TCDF, that were >50%. The normalised data was used to produce a dose-response
curve which allowed calculation of the EC50. Comparison of EC50 is a useful
method but is only applicable when the dose-response curves are identically
Richard Wall
67
positioned on the Y-axis, differing only in their position on the X-axis (Whyte et
al., 2004). The curves of four separate TCDD assays were compared to
demonstrate the robustness of the method used and the reliability of the data
collected. Multiple determinations of the EC50 gave an average value of 35 pM
(S.D. = ± 5.8 pM) with considerable overlap of means and 95% confidence
intervals.
4.2 Partial Agonism studies
4.2.1 Agonist Properties
The results demonstrate that there were several compounds that are potent
agonists of the AhR and induced CYP1A1 RNA with nanoMolar EC50 values. It
was possible to conclude from this data that, with the exception of CH 223191, all
of the compounds tested had agonist properties since they induced CYP1A1 RNA.
4.2.2 Comparison of EC50 with Previous Literature
The average EC50 of TCDD found in this research was similar to that found by
several other authors (Bazzi, 2008; Hilscherova et al., 2001; Sanderson et al.,
1996; Schmitz et al., 1995; Silkworth et al., 2005). The majority of research
summarised in table 3.1 was conducted in rat H4-IIE cells, however there are
several salient differences. The treatment times varied between 4 hours (Bazzi,
2008) and 72 hours (Hilscherova et al., 2001), and another difference is the
method of measurement used which, for the majority of studies, was measurement
of EROD activity, with only two studies using RT-PCR (Bazzi, 2008; Silkworth
et al., 2005). The study by Silkworth et al. (2005) uses rat liver hepatocytes but
Richard Wall
68
was included as a further example of an EC50 found using a method more closely
related to mRNA induction.
Table 4.1: Comparison of EC50 with previous literature –
a4 hours treatment, b24 hours
treatment, c48 hours treatment, d72 hours treatment, eRat liver hepatocytes, *± Standard
Deviation/Standard Error, Method1: Method used in each experiment. RT-PCR: Real-time
Polymerise Chain Reaction, EROD: Ethoxyresorufin-O-deethylation, Invader: RNA invader®
invasive cleavage amplification assay (consists of an upstream oligonucleotide and a probe) see
Silkworth et al. (2005).
4.2.2.1 TCDD, 3-MC and DF 203
TCDD is a well studied compound, used as a reference compound in many of the
studies. The data shows that all the EC50s from each paper are within a ~10-fold
Compound with EC50 (95%
CI) from this paper
Method1
EC50 (95% CI or SD/SE*)
from literature
Author of
literature
TCDD
35 pM (22 pM – 56 pM)
RT-PCRa 40 pM (± 13 pM*) Bazzi 2008
Invader 2.7 pM (1.2 pM – 5.9 pM)e Silkworth 2005
ERODc 41 pM (23 pM – 74 pM)e Silkworth 2005
ERODb 11.8 pM (± 3.9 pM*) Clemons 1997
ERODc 9.0 pM (± 2.1 pM) Clemons 1998
ERODd 34.5 pM (± 1.96 pM*) Hilscherova 2001
EROD 50 pM (± 13 pM*) Schmitz 1995
ERODd 10 pM Peters 2004
ERODd 19.6 pM (± 5.6 pM*) Sanderson 1996
3-MC
2.3 nM (1.3 nM – 3.8 nM)
RT-PCRa 9 nM (7 nM – 13 nM) Bazzi 2008
TCDF
5.8 nM (2.8 nM - 11 nM)
ERODb 45.0 pM (± 15.2 pM*) Clemons 1997
PeCDF
2.2 nM (1.4 nM - 3.4 nM)
ERODd 76 pM (± 0.4 pM*) Sanderson 1996
PCB 126
765 pM (645 pM - 907 pM)
Invader 1.5 nM (0.5 nM – 4.3 nM)e Silkworth 2005
ERODc 330 pM (110 pM – 990 pM)e Silkworth 2005
ERODd 264 pM (± 0.4 pM*) Sanderson 1996
ERODd 100 pM Peters 2004
DF 203
1.5 µM (1.2 µM – 1.8 µM)
RT-PCRa 3 µM (0.9 µM – 13 µM) Bazzi 2008
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difference of each other, with an average EC50 of ~25 pM, which compares well
with this paper (Average EC50 = 35 pM). Bazzi (2008) assayed 3-MC and DF 203
with similar results to those found by this paper. The EC50 for 3-MC in this paper
was 5.8 nM (95% CI = 2.8 nM – 11 nM) which compares well to the findings of
Bazzi (2008) which was 9 nM (95% CI = 7 nM – 13 nM). Furthermore, Bazzi
(2008) found the EC50 of DF 203 to be 3 µM (95% CI = 0.9 µM – 13 µM) which
compared well with the EC50 found in this paper which was 1.5 µM (95% CI =
1.2 µM -1.8 µM). This confirms the previous conclusion of other papers, that DF
203 has agonist properties (Bazzi, 2008; Loaiza-perez et al., 2002).
4.2.2.2 TCDF and PeCDF
A 100-fold difference in the EC50 for TCDF, in comparison with the literature,
was found (Clemons et al., 1997). Similarly, there is an 80-fold difference in the
EC50 found for PeCDF compared with the literature (Sanderson et al., 1996).
Calculation of the relative potency (REP) in relation to TCDD gave values of
0.006 and 0.016, for TCDF and PeCDF, respectively. This compares
insufficiently with the WHO TEFs of 0.1 and 0.3 for TCDF and PeCDF,
respectively. Review of the method reveals one possible explanation, in that the
vehicle used to dissolve the compounds, was DMSO. In order to reduce the
number of variables between experiments, the same solvent was used as a vehicle
for each compound where possible. However, previous authors dissolved TCDF
in p-dioxane (Bazzi, 2008) or isooctane (with further dilutions in DMSO)
(Clemons et al., 1997), with PeCDF also dissolved in isooctane (Sanderson et al.,
1996). Solubility of the compounds into the vehicle was only visually assessed
and therefore complete solubility may not have occurred in DMSO. This would
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mean the EC50 estimates may show a higher concentration than in other research.
This should not have any impact on agonism experiments other that the
concentration used to give 15% of maximal induction would be lower than stated
for TCDF and PeCDF. Another possible explanation for the differences seen
between the EC50 found in this paper and previous research is the use of RT-PCR
instead of EROD activity. Clemons et al. (1997) found the EC50 for TCDF only 1-
2 fold higher than TCDD. Furthermore, Clemons et al. (1997) showed a ~7-fold
increase in the EC50 of the EROD activity of TCDF between exposures of 6 and
72 hours in H4-IIE Rat liver cells. In order to test the hypothesis that treatment
duration affects the induction by TCDF, the effects at different exposure times
could be assessed in a similar experiment as described in this paper (section 3.4).
4.2.2.3 PCB 126
The literature provided a wide range of values for the EC50 of PCB 126 ranging
from 100 pM (Peters et al., 2004) to 1.5 nM (Silkworth et al., 2005). The EC50
found in this paper (765 pM) does lie comfortably within this range but with the
majority of previous research utilising the EROD activity assay (Clemons et al.,
1998; Peters et al., 2004; Sanderson et al., 1996; Silkworth et al., 2005),
comparison is complex. The REP was calculated in relation to TCDD which was
0.05, compared with 0.1 predicted by the WHO TEF. Although lower than the
WHO TEF, it does compare better with previous authors who measured 0.03
(Silkworth et al., 2005) and 0.75 (Sanderson et al., 1996) in rat liver hepatocytes
and H4-IIE rat liver cells, respectively. Nevertheless, there is a slight discrepancy
between research found in this paper and that published by the WHO. In this
paper, PCB 126 was dissolved in DMSO as described by previous authors
(Clemons et al., 1998; Silkworth et al., 2005), although Sanderson et al. (1996)
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used isooctane as a vehicle, presumably to reduce the number of variables. The
slight discrepancy between values could therefore be due to the method of
measurement (EROD activity) which was shown to be inhibited by other PCBs
(Clemons et al., 1998) however there is no previous evidence of this.
4.2.3 Effects of Partial Agonism on CYP1A1 RNA Induction
The four agonists that were tested, 3-MC, TCDF, PeCDF and PCB 126, showed
no antagonistic properties in the particular experiments carried out in this study.
Clemons et al. (1998) tested TCDD in the presence of various PCBs including
PCB 126 and found that the compound also had no effect on induction by TCDD
(Clemons et al., 1998). Walker et al. (2005) conducted mixture experiments in
rats with the occurrence of neoplastic and nonneoplastic effects as an endpoint.
Although the WHO additivity method was not directly applied, the authors did
conclude that PCB 126 had no observable partial agonistic effects.
By comparing the 95% confidence intervals of the EC50 from each partial agonism
experiment with that of TCDD alone it can be concluded that there was no
significant difference in the concentrations of TCDD required for CYP1A1 RNA
induction. This shows that the four agonist compounds tested do not have
detectable antagonist properties in rat H4-IIEC3 cells, when compared with
TCDD. If the compounds tested had an effect on the concentrations of TCDD
required for induction; a shift of the dose-response curve to the right would be
observed in a similar way to figure 3.14 (1 µM DF 203) and figure 3.16 (10 µM
CH 233191). The EC50 determinations have 95% confidence intervals spanning a
3-5 fold range, and so these experiments are sufficiently powered to detect
antagonism that shifts the EC50 of TCDD by ~5-fold. A compound with a high
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intrinsic efficacy does not need to bind to as many receptors as a compound with a
low intrinsic efficacy, such as a partial agonist, to reach the same response
(Kenakin, 1997). Given the comparatively low dose of potential antagonist tested
(~15% of maximal induction), a compound would need to have intrinsic efficacy
which is >90% antagonistic to be detected in this assay.
4.2.4 Partial agonism by DF 203
The agonist only curve confirms previous research that describes DF 203 as
having agonist properties (Bazzi, 2008; Loaiza-perez et al., 2002). Induction of
CYP1A1 by TCDD in the presence of 1 µM DF 203 demonstrated that the
compound had partial agonistic properties. Research by Bazzi (2008)
demonstrated that DF 203 had a high binding affinity (Ki) but low efficacy. This
difference between affinity and efficacy could be explained by DF 203 having
antagonistic properties. From the dose-response curve in figure 3.16, this
concentration should be ~300 nM DF 203, however this provided no change in
induction when in the presence of TCDD (Figure 3.17), indicating that the
concentration was too low to induce CYP1A1 RNA (i.e. 15% of maximal
response) which one would assume was therefore also too low to antagonise
TCDD. A second dose-response curve was then established using a higher
concentration of 1 µM DF 203 (Figure 3.18). In this case, it would appear that the
estimation of 15% of maximal response is too high but comparable to that of the
original agonist only dose-response curve, which is also supported by previous
research (Bazzi 2008). It was possible to calculate the EC50 of the curve which
was 726 pM (95% CI = 69 pM-7.6 nM) which was found to be significantly
different from TCDD alone (EC50 = 34 pM, 95% CI = 18 pM - 63 pM). It is
therefore possible to conclude that this compound has both agonist and antagonist
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properties. The fact that DF 203 has been shown to have antagonistic properties is
a novel finding not tested previously. Bazzi (2008) assayed a congener of DF 203
known as 5F 203, which is also an experimental synthetic anti-tumour agent.
Bazzi (2008) calculated the EC50 for 5F 203 to be 3µM (95% CI = 1.3 µM –
7.7µM), similar to the EC50 for DF 203, also demonstrating that it had agonistic
properties but with a low potency compared with TCDD (Bazzi 2008).
Furthermore, the Ki was found to be 2.8 nM (2 nM – 5 nM) which is 5-fold lower
than the Ki for DF 203 (9.9 nM), suggesting that 5F 203, is a slightly stronger
antagonist than DF 203. In agreement with this, Bazzi (2008) found that 1 PM 5F
203 shifted the TCDD dose-response curve by ~100-fold, whereas this report
finds that 1 PM DF 203 shifted the TCDD dose-response curve by ~20-fold. Thus
the empirical finding is that DF 203 has slightly lesser antagonist properties than
5F 203.
4.2.5 Antagonistic properties of CH 223191
The inhibition of TCDD to induce CYP1A1 RNA by CH 223191 was measured.
Figure 3.20 shows treatment with TCDD in the presence of 10 µM CH 223191
however the concentrations of TCDD required for induction are too low to allow
calculation and comparison of the EC50. Potentially it is possible to compare the
two curves (TCDD in presence and absence of CH 223191) and see that there is a
considerable shift of the curve to the right which would indicate antagonism of
TCDD however it isn’t possible to quantify this with the given data. Figure 3.19
shows that when 300 nM CH 223191 was added to TCDD treated cells, the
antagonist had little or no observable effect of induction of CYP1A1 RNA by
TCDD, even though an effect was observed by Kim et al. (2006). There are two
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major factors that might explain this difference. Firstly, HepG2 human hepatoma
cells were tested instead of H4-IIE rat liver cells and secondly, cells were pre-
treated with CH 223191, one hour before treatment with TCDD, which was not
done in this paper. This could explain the discrepancy seen when treating cells
with 300 nM CH 223191, which should have produced an effect according to data
from Kim et al. (2006) but in this paper had no observable antagonistic effects
(figure 3.19). Furthermore, Kim et al. (2006) measured a single concentration of
TCDD in the presence of only three concentrations of CH 223191, visualised
using Reverse Transcriptase- PCR, which can be quite inaccurate and unreliable.
4.3 Time Dependent Induction Assays
4.3.1 3-Methylcholanthrene vs. 2,3,7,8-Tetracholodibenzo-p-dioxin
Previous authors (Poland et al., 1974; Riddick et al., 1994; Sekimoto et al., 2004;
Xu et al., 2005) have described 3-MC as being metabolised rapidly by P450
enzymes. In the time-dependent induction assay conducted in this paper, cells
were treated with 3-MC at various concentrations for 4 hours and 24 hours. The
EC50s were calculated for each curve and compared, demonstrating a 40-fold
significant difference with no overlapping of the 95% confidence intervals. This
difference in induction thresholds between 4 and 24 hours could be due to a
variety of factors including; metabolism of the ligand, degradation of CYP1A1
RNA over time or reduction in AhR-mediated induction of CYP1A1 RNA.
Firstly, 3-MC has a reported half-life of ~16 hours in rats (Aitio et al., 1974)
although no experimental work has actually quantified the half-life in H4IIE cells,
research does show a decrease of the half-life of 3-MC compared with TCDD
(Aitio et al., 1979). Nevertheless using this estimation as a guide, a reduction of
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~40% of 3-MC could be expected in cells over a period of 24 hours. Therefore it
could be concluded that this will have a huge impact in the reduction of the
induction of CYP1A1 RNA by 3-MC between 4 and 24 hours. Cells were also
treated with TCDD in a separate experiment for 4 and 24 hours to allow
comparison to 3-MC. TCDD has a half life of 17-31 days in rats (Van den Berg et
al., 1994) so metabolism would not be expected to affect induction of CYP1A1
RNA. However despite this, a 4-fold significant difference in TCDD induced
CYP1A1 RNA levels was found between 4 and 24 hours. Other literature shows
no significant change in EC50 of TCDD up to 72 hours after treatment (Bazzi,
2008; Clemons et al., 1997). The important advantage of this study over previous
work (Bazzi, 2008) is the greater statistical power for estimating the EC50
produced from the increased number of concentrations utilised and the use of
simultaneous normalisation of CYP1A1 RNA against the two references genes.
This would make the method used in this paper more adept at observing minute
changes in induction. Another explanation for this discrepancy is that TCDD is
known to be lipophilic so over 24 hours, TCDD may have fallen slightly out of
solution or more likely adsorbed to the 96-well plate or even the densely packed
lipids making up the cell membrane.
With the data collected, it isn’t possible to comment on the mechanism by which
CYP1A1 RNA levels decreased with regards to TCDD. However, the degradation
of CYP1A1 RNA or the reduction in AhR-mediated induction of CYP1A1 RNA
may have an important role. Theoretically there must be a system within the cell
to remove un-necessary RNA. Recent studies have described small interfering
RNAs (siRNA) which degrade RNA and interfere with the expression of a
specific gene (Hannon et al., 2004). Reduction of CYP1A1 could be attributed to
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naturally occurring siRNAs, as well as the ligand being metabolised by P450
enzymes over time. Another explanation is that there may be a reduction in the
initial AhR-mediated induction of CYP1A1. This reduction could be attributed to
any one of the stages of the mechanism of action; however it would seem
conceivable that the quantity of AhR may decrease quickly in the presence of a
high concentration of a specific AhR ligand, which would in turn decrease the
induction of CYP1A1 RNA. Giannone and co-workers (1998) confirmed that the
AhR population rapidly decreases following treatment with TCDD and can
remain low for at least 24 hours after exposure has ended (Giannone et al., 1998),
however the authors did acknowledge the fact that CYP1A1 levels remained
constant 72 hours after treatment despite reduced AhR levels. Superinduction
appears to show an increase in response as CYP1A1 RNA levels build up because
protein translation is inhibited (Ma et al., 2000). Ma et al., (2000) demonstrated
this using three compounds which increased the induction of CYP1A1 by TCDD,
two of which work by inhibiting AhR degradation (Ma et al., 2000) showing the
effect of reducing the depletion of AhR, at least in the presence of certain other
compounds, can maintain CYP1A1 levels. Consequently, although the data
required to make a reliable conclusion is not available, it can be hypothesized that
both of these additional reasons for a decrease in AhR activity, could be
associated with the differences observed between 4 and 24 hours in TCDD with
the large addition of metabolism affecting 3-MC. Future work would reconfirm
the values found for the two agonists and would look into explanations for
differences in AhR binding and degradation.
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4.4 Bioassay Limitations and Future Use
4.4.1 Limitations of assays
This paper looked at potential antagonist compounds individually or in a mixture
with only TCDD. In the environment, these compounds will be in complex
mixtures with a large variety of dioxin-like and non dioxin-like compounds, and
therefore the compounds tested could behave differently. It isn’t realistic to
measure the interaction between every compound or to measure every conceivable
mixture variation however using this data may allow the estimation of the
characteristics of a particular compound in a given situation. This is what makes
the TEQ system such a powerful risk assessment tool by collecting data similar to
this paper on individual compounds or small mixtures, and using it to predict how
the compound will act in a complex mixture. Furthermore, assays were performed
under control conditions in H4-IIEC3 bioassays which may not be fully
representative of how the compounds may interact in vivo.
The benefits of using H4-IIE cells are well researched including excellent growth
properties, low basal AHH and CYP1A1 levels, with a high degree of
responsiveness towards dioxin-like compounds (Benedict et al., 1973). Research
by Niwa et al. (1975) demonstrated the extreme potency of TCDD in H4-IIE cells
(Niwa et al., 1975). Authors have shown comparative results from H4-IIE cells to
structure-activity relationships, binding assays and in vivo responses in rats (Safe,
1986) furthermore H4-IIE cells have high levels of AhR. In this paper the effects
of AhR antagonists were assayed, however as previously discussed a compound
with antagonistic properties will bind to the Ah receptor but will not activate it.
Therefore by choosing a cell line with decreased number of Ah receptor,
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observation of antagonistic effects may become more easily detectable. A
comprehensive study in rat cell lines showing levels of Ah receptor has not been
conducted previously, however cell types with low levels of AhR include brain,
kidney and skeletal muscles as demonstrated by Dolwick et al. (1993) in human
tissues (Dolwick et al., 1993).
4.4.2 Future application of bioassay
There are several PCBs which exhibit both agonistic and antagonistic properties
which could be further investigated in relation to risk assessment and the
additivity approach (Chu et al., 2001; Clemons et al., 1998; Schmitz et al., 1995).
Clemons et al. (1998) combined various concentrations of TCDD with different
PCBs and showed that some of the PCBs had antagonistic effects which would
produce a lower toxic potency than that predicted by the TEQ additivity approach.
This conclusion was further complicated by the differing effects of antagonistic
PCBs in complex mixtures of HAHs. Other compounds not currently included
within the WHO TEQ compounds, such as polybrominated diphenylethers
(PBDEs), could also have implications on risk assessment in complex
environmental mixtures. Peters et al. (2004) measured TCDD in the presence of
various PBDEs and found that several of the compounds had inhibitory effects,
producing a significantly lower response than TCDD alone. These would
potentially affect the TEQ estimation if not accounted for. A more detailed
investigation of naturally occurring agonists should be conducted.
4.5 Conclusion
The aim of this paper was to observe and where possible, quantitate the
antagonistic effects for several of the most potent and prevalent dioxin-like AhR
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ligands. It was found that the four agonists tested did not have antagonistic
properties however this paper has successfully demonstrated the antagonistic
properties of DF 203, when in the presence of TCDD. Furthermore, the
antagonistic effects of CH 223191 on the induction of CYP1A1 RNA by TCDD
was verified and confirmation of a decrease in the ability to activate the AhR over
time by 3-MC was demonstrated. The method designed for measuring the
activation of the AhR by different agonists was successfully applied to all of the
compounds used in this experiment. RT-PCR, with increased sensitivity of
CYP1A1, decreasing costs and faster output; should become the default method
for measurement in the future. Furthermore, investigation into the bioassay may
improve the observation of antagonistic effects with increased knowledge of
compound metabolism derived from the induction measured at different exposure
times. Finally, future work will need to analyse the potential effects of natural
ligands, as well as partial agonists, on the TEQ calculated using the additivity
approach.
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